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1 Introduction and Objective 
 
Vaccines have led to the elimination or control of several infectious diseases, including measles, 
mumps, rubella, tetanus and smallpox. Generally, a long-lasting immune response can be 
achieved when using live, attenuated vaccines. However, mutation to the virulent version is 
always possible. Therefore, non-live vaccines, which are less dangerous, are desirable.  
Novel vaccines consist of recombinant proteins that are safe to use, but often poorly 
immunogenic. In order to achieve a sufficient immune response adjuvants are essential. The 
requirements for an adjuvant are dependent on the type of immunogenic substance that is used as 
a vaccine. Despite the high demand only a few adjuvants are currently available for the use in 
humans and animals. At the moment, aluminum salts and oil-in-water (o/w)-emulsions are 
typically used as adjuvants (Tetsutani and Ishii, 2012). New adjuvants are needed for the 
challenges of finding vaccines for malaria, autoimmune diseases and cancer (Heegaard et al., 
2011).  
An innovative approach of developing modern adjuvants is the design of particulate antigen 
delivery systems. These, typically polymeric, particles that are in a size range of micro- and 
nanoparticles can be used as drug carrier systems. Such drug carriers can target antigen 
presenting cells, which is crucial for long-lasting immunity (Singh et al., 2007). 
The mode of action of the drug delivery system can be modified by the particle size as well as the 
physicochemical property (Lamprecht, 2010). Therefore, the aim of this work was the 
development and characterization of polymeric micro- and nanoparticles for the antigen delivery 
using biodegradable and biocompatible polymers. In this work poly(D,L-lactide-co-glycolide) 
(PLGA) was used as a polymer, because PLGA-microparticles and PLGA-nanoparticles already 
showed a potential to be used as vaccine adjuvants (Kasturi et al., 2011; Singh et al., 2004). 
This work deals with three major parts. First, protein loaded nanoparticles were prepared by the 
double-emulsion method. This method is the gold-standard to entrap hydrophilic drugs like 
proteins into polymeric nanoparticles (Lamprecht et al., 2000b). It has been assumed that the 
protein is entrapped inside the nanoparticles, although this notion was never accurately proven by 
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a suitable imaging technique (Lamprecht et al., 1999). Scanning electron microscopy (SEM), 
transmission electron microscopy (TEM) and atomic force microscopy (AFM) were mainly used 
in the past to characterize the morphology of microparticles and nanoparticles (Blanco and 
Alonso, 1997; Lamprecht et al., 2000b; Zambaux et al., 1998). However, only the shape and the 
particle size of the nanoparticles are visible using these imaging methods. In the presented work 
we characterized the physicochemical properties and investigated the interior morphology of the 
prepared nanoparticles using ion-milling coupled field-emission scanning electron microscopy. 
The goal was to achieve a comprehensive understanding of these nanocarriers regarding its 
morphology. 
In the second part, polymeric nanoparticles for the parental use as vaccine adjuvants were 
prepared. Based on the findings about the morphology of nanoparticles prepared by the double-
emulsion method, a simplified preparation method was employed. A comprehensive 
characterization of the nanoparticles, including analysis of the particles size, loading rate, zeta 
potential and release studies, to obtain a thorough understanding about the carrier system was the 
aim of this work. Furthermore, an investigation about the toxicity and uptake abilities of the 
prepared nanoparticles into a macrophage cell line and in-vivo experiments in mice to examine 
the adjuvant effect of the nanoparticles was of high importance. The aim was to find out, if 
protein loaded nanoparticles are beneficial as a vaccine adjuvant and if the surface properties of 
the nanoparticles have an influence on the immune response. 
Microparticles also showed a potential as vaccine adjuvants (O’Hagan and Singh, 2003). Protein 
loaded micorparticles can be prepared using the double-emulsion method. In the third part of this 
work, the aim was to investigate the effect of different processing parameters of polymeric 
microparticles prepared by a double-emulsion method. Also the influence of different polymers 
on the microparticle properties was investigated.  
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2 Background 
2.1 Vaccines 
First achievements in the field of immunological research can be traced back to the 15th century. 
In China scabs of smallpox were pulverized and insufflated to gain immunity. This very 
dangerous procedure did have a mortality rate of around 2%. In 1798 Edward Jenner was able to 
describe a protective effect of cowpox against smallpox that was safe in children and adults 
(Schütt and Bröker, 2009). 
The goal of vaccination is the induction of an immunologic memory to protect against a disease. 
Vaccines can be classified in live, attenuated vaccines, and inactivated vaccines (Foged et al., 
2002). Live, attenuated vaccines contain a version of bacteria or viruses that cannot cause the 
disease but elicit a strong immune response. However, viruses and bacteria can mutate back into 
the virulent form leading to an outbreak of the illness. Targets for live, attenuated vaccines are 
measles, mumps, rubella, and chicken pox (NIH, 2012). 
Inactivated vaccines contain killed and non-virulent microorganisms that cannot mutate to the 
virulent version. They are safer to use, but they also induce a reduced immune response. Toxoid 
vaccines, e.g. vaccines against diphtheria and tetanus, are inactivated bacterial toxins. Subunit 
vaccines contain only the antigens that stimulate the immune system the most. The antigens can 
be derived directly from the microorganism responsible for the disease or they are genetically 
engineered resulting in recombinant proteins that pose as antigens. Another vaccine type are 
conjugate vaccines. Some bacteria have polysaccharides as a compound of the cell wall material, 
linking these polysaccharides to proteins creates conjugate vaccines like the Haemophilus 
influenzae type B vaccine (Rosenthal and Zimmerman, 2006; Schütt and Bröker, 2009). All of 
these vaccines show a lower immune response than live, attenuated vaccines, therefore adjuvants 
are needed to enhance the immunogenic effect. 
Fatal diseases like smallpox have been successfully eradicated through the use of vaccines. Other 
diseases like measles, mumps and chicken pox are not as common as they were before the use of 
vaccines. Some people cannot be immunized with all vaccines due to immunosuppression. That 
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is why it is important to vaccinate the majority of the population to decrease the likelihood of 
spreading a disease. This effect is referred to as herd immunity.  
The Robert Koch Institute is responsible for recommending a vaccine schedule in Germany 
(Table 1). Standard vaccines should be taken by the whole population. Depending on the type of 
work, age, gender and travel destinations additional vaccines might be necessary.   
 
Table 1: Vaccine schedule for Germany recommended by the STIKO (STIKO, 2013) 
 Vaccine target 
Standard vaccination Diphtheria 
Haemophilus influenza type b 
Hepatitis B 
Measles 
Meningococcus 
Mumps 
Pertussis 
Pneumococcus 
Poliomyelitis 
Rubella 
Tetanus 
Varicella 
Vaccination for high-risk groups Cholera 
Hepatitis A 
Human papillomavirus 
Influenza 
Rabies 
Thick-borne encephalitis 
Typhoid 
 
Even though a lot of diseases can already be prevented by using vaccines, there is still a vast 
number of infectious diseases for which vaccines or safer and more efficacious versions of those 
available are needed. There are unmet targets for vaccine development like the human 
immunodeficiency virus (HIV), and cytomegalovirus, bacteria such as Pseudomonas aeruginosa, 
Neisseria gonorrhea, Mycobacterium tuberculosis, and parasitic diseases like malaria. Other 
vaccine targets include cancer, autoimmune diseases, hypertension and Alzheimer’s (Rosenthal 
and Zimmerman, 2006). 
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Vaccines help developing immunity by imitating an infection. Essential for initiating immune 
responses are antigen-presenting cells like dendritic cells and macrophages (Unanue, 1984). 
Immature dendritic cells are taking up proteins in the periphery to monitor the environment. After 
dendritic cells are activated by antigens, the cell matures and migrates to lymph nodes. During 
the maturation the antigen is processed into small fragments and these fragments are then 
presented at the cell surface by coupling the antigens to major histocompatibility complex 
(MHC) molecules. CD4+ T cells recognize antigenic peptides coupled with MHC class II 
molecules and CD8+ T cells bind to MHC class I molecules. Activated CD4+ T cells support the 
activation of B cells, whereas CD8+ T cells differentiate into cytotoxic cells capable of killing 
pathogens (Fig. 1) (Schütt and Bröker, 2009; Siegrist, 2008). T cell responses are part of the 
cellular immunity. The humoral immunity is triggered by B cell responses, which leads to 
antibody production. B cells are also activated by dendritic cells. They bind to the antigen 
presented by dendritic cells with immunoglobulins on their surface. This causes the B cells to 
differentiate to plasma cells that produce antibodies, which appear in low levels in the serum 
within a few days of immunization. Some B cells differentiate to memory B cells. These memory 
B cells are activated through contact with the specific antigen, which leads to maturation to 
plasma cells and the production of IgG antibodies. The short life span of the plasma cells has the 
consequence that antibody titers decline rapidly after one immunization. The antibodies will 
eventually disappear after a primary response, when using non live vaccines. That is why booster 
immunizations after several weeks are necessary. Following a secondary immunization, a rapid 
increase of the antibody titer can be observed, as memory B cells are activated. They differentiate 
to plasma cells and high-affinity antibodies are secreted (Rosenthal and Zimmerman, 2006; 
Siegrist, 2008). 
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Fig. 1: (1) CD 4+ T cell binds on MHC II at cell surface of antigen presenting cells; (2) both 
antigen presenting cells and CD 4+ T cells release cytokines that activate (3) B cells and CD 8+ T 
cells; modified from (Dario-Becker, 2013; Meeusen et al., 2007; Siegrist, 2008) 
 
Live, attenuated vaccines rapidly spread throughout the body after injection and dendritic cells 
are activated at multiple sites, which is similar to the pattern occurring after a natural infection. 
They multiply at the injection site and in the periphery. Consequently, the immunogenicity of live 
vaccines is generally higher compared to non-live vaccines. Furthermore, the injection site is not 
important when using live vaccines, because of the fast dissemination of the viral or bacterial 
particles. Non live vaccines cannot multiply, therefore the activation of innate responses are 
limited in time and space, which is why the administration route is more important in comparison 
to live vaccines (Siegrist, 2008).  
 
2.2 Adjuvants 
Many vaccines are not immunogenic enough to elicit an immune response that would trigger 
immunity. Especially non live-vaccines are showing a low immunogenic potency when 
administered alone. Moreover, proteins posing as antigens have to withstand harsh conditions to 
maintain their composition and thereby maintaining their immunogenic potential. Recombinant 
proteins are safer to use than live, attenuated vaccines, but less immunogenic. Hence, substances 
that enhance the immune response of the safe, but poorly immunogenic antigens are in demand 
(Aucouturier et al., 2001). 
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Adjuvants are compounds that increase the immune response, when used in combination with a 
specific antigen (Singh and O'Hagan, 2003). The efficacy of many vaccines is dependent on the 
adjuvants as antigens have become more purified (Aucouturier et al., 2001; Korsholm, 2010).  
The application of an adjuvant can have different benefits and different adjuvant types are 
available. Immunomodulatory adjuvants can induce either a predominantly Th1 or Th2 type 
immune response, dependent on which adjuvants are being used. Another type of adjuvants are 
substances that can prolong the interaction between the antigen and antigen presenting cells. 
Furthermore, adjuvants have the potential to be antigen delivery systems that target antigen 
presenting cells like dendritic cells (Cox and Coulter, 1997).  
The exact mode of action of adjuvants is still not fully understood, but is has been suggested that 
a “depot effect” and an induction of an inflammation might be mechanisms of adjuvant 
effectiveness (Heegaard et al., 2011; Kuroda et al., 2013).  
A lot of different adjuvants are available or currently in development (Table 2). The most 
commonly used adjuvants are aluminum salts. They are FDA approved and safe to use in humans 
and animals (Tetsutani and Ishii, 2012). Generally, an aluminum hydroxide or aluminum 
phosphate gel is used, which binds the immunogenic substance via electrostatic interaction. A 
prolonged interaction of the antigen with cells of the immune system is possible because of the 
gel-like structure. Furthermore, it is suggested that aluminum salts activate the innate immune 
response, which in combination with the immunogenic substance subsequently leads to an 
adaptive immunity (Kuroda et al., 2013).  
Freund’s Adjuvant is an oil based adjuvant. It has been successfully used in veterinary vaccines, 
but remains inapplicable for humans, because of toxicity concerns. Freund’s Adjuvant does 
however elicit a strong immune response, which can also be contributed to the high inflammatory 
effect of the mineral oil after administration (Heegaard et al., 2011). 
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Table 2: Ingredients of conventional adjuvants; modified from (Cox and Coulter, 1997; 
Heegaard et al., 2011; Rosenthal and Zimmerman, 2006; Singh and O'Hagan, 2003; Tetsutani 
and Ishii, 2012)  
Adjuvant Ingredient 
Freund’s Adjuvant, complete Mycobacterium tuberculosis, paraffin oil, 
mannide monooleate 
Freund’s Adjuvant, incomplete Paraffin oil, mannide monooleate 
Alum Aluminium hydroxide, aluminium phosphate 
MF59® Squalene, polysorbate 80, Span 85 
AS03 Squalene, polysorbate 80, DL-α-tocopherol 
AS04 Aluminium hydroxide, monophophoryl lipid A 
Immune stimulating complexes (ISCOMs) Cholesterol, phospholipid, Quillaia saponins 
MPL Monophophoryl lipid A 
CpG 
Carbopol 
Oligunecleotide 
Synthetic, anionic polymer 
Ribi® Squalene, polysorbate 80, MPL,  
Montanide ISA51 Mineral oil, surfactant, immunomodulator 
Syntex adjuvant formulation (SAF) Squalene, polysorbate 80, muramyl dipeptide 
derivative (threonyl-MDP) 
Titermax® Squalene, block copolymer, microparticulate 
stabilizer 
Proteosomes Aggregates of bacterial transmembrane 
proteins 
Virosomes Virus-derived transmembrane proteins 
Mineral salts Aluminium salts or calcium phosphate 
LPS Lipopolysaccharides 
Particulate adjuvants Microparticles, nanoparticles, liposomes 
 
A better approach than oil based adjuvants is an o/w-emulsion. MF59® and AS03 are examples 
for o/w-emulsions and are currently used in influenza vaccines. MF59® and AS03 induce a high 
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degree of cell recruitment of monocytes and dendritic cells, which might be responsible for the 
adjuvant effects (Tetsutani and Ishii, 2012).  
ISCOMs are matrices that are formed after interaction of saponins, cholesterol and phospholipids. 
These open cage-like structures have the immunogenic substance incorporated inside the cage. 
The mode of action is probably via targeting of immune cells (Cox and Coulter, 1997). 
Immune cells have toll-like receptors on their surface, which are able to identify pathogens. The 
pathogens are detected by their pathogen-associated molecular pattern (PAMP). Adjuvants that 
pose as PAMPs can be ligands to toll-like receptors and therefore initiate an immune response. 
MPL as well as CpG have been identified as toll-like receptor agonists (Heegaard et al., 2011). 
Adjuvants play an important role in vaccines and the battle against many diseases. However, only 
very few adjuvants have been approved for the use in humans. Novel, safe and efficient adjuvants 
are needed to overcome the challenges of new, poorly immunogenic antigens. Moreover, 
innovative adjuvants are needed for the challenging task of finding vaccines for malaria, cancer 
and autoimmune diseases.  
 
2.3 Nanoparticles 
Nanotechnology is an important and novel approach to overcome drug delivery challenges. 
Nanoparticles can be defined as particles with diameters ranging from 1 nm to 1000 nm. Further, 
they can be subdivided into nanocapsules and nanospheres (Fig. 2). Nanocapsules have the drug 
usually encapsulated in an inner liquid core that is surrounded by a polymeric shell. Nanospheres 
consist of a matrix in which the drug is encapsulated or the drug is adsorbed at the surface of the 
nanospheres (Pinto Reis et al., 2006).  
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Fig. 2: Different types of polymeric nanoparticles (Vauthier and Bouchemal, 2009) 
 
Polymeric nanoparticles are of great interest as carriers of therapeutic drugs in controlled release 
applications (Mundargi et al., 2008). With an improved drug delivery directly to the site of action 
the overall toxicity can be reduced (Cheng et al., 2012). Nanoparticles can penetrate deep into 
tissues and are usually taken up efficiently by cells. Moreover, the drug dosage can be reduced 
and drugs are protected from degradation, increasing the drug stability (Bala et al., 2004). 
Requirements for polymeric nanoparticles for parental use include biocompatibility, suitable 
biodegradation and drug compatibility (Lu et al., 2009). Due to a better transport of drugs across 
absorption membranes, oral delivery of APIs that normally have no bioavailability like heparin 
(Hoffart et al., 2006) or insulin (Viehof et al., 2013) is possible (Viehof and Lamprecht, 2013).  
The uptake and pathway of nanoparticles into cells was the target of various studies (Fleischer 
and Payne, 2012; Hillaireau and Couvreur, 2009; Treuel et al., 2013; Wachsmann and 
Lamprecht, 2012; Walczyk et al., 2010). Nanoparticles can be internalized in cells through 
phagocytosis or other endocytic pathways. The other endocytic pathways can be further 
categorized in clathrin-mediated endocytosis, caveolae-mediated endocytosis and 
macropinocytosis (Fig. 3) (Hillaireau and Couvreur, 2009). Nanoparticles are being “tagged” by 
proteins (opsonins) if phagocytosis occurs. This opsonization enables the nanoparticles to attach 
to cells, and subsequently to be phagocytosed.  
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Fig. 3: Pathways of nanoparticles into cells (Hillaireau and Couvreur, 2009) 
 
Nanoparticles have a benefit in the treatment of a wide range of diseases and also possess the 
ability to function as supporting agents for the diagnosis of diseases, e.g. imaging contrast agents 
in diagnostic ultrasound (Lu et al., 2009). Delivery of vaccines and adjuvants using nanoparticles 
is possible and needs to be further investigated (Singh et al., 2007). The delivery of interferon 
and the delivery of DNA with nanoscale drug carriers offer the potential of the treatment of a 
variety of diseases, e.g. neurodegenerative illnesses, cancer and cardiovascular diseases 
(Mundargi et al., 2008). Treatment of cancer with nanoparticles showed promising results in 
animal studies, as nanoparticles showed the ability to accumulate in tumor tissue (Doll et al., 
2013). Furthermore, the delivery of drugs across the blood-brain barrier can be enhanced when 
using surfactant coated nanoparticles (Soppimath et al., 2001). Several products based on 
nanomedicine containing API’s can already be found on the market (Table 3).  
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Table 3: Selection of nanoparticulate drug delivery systems on the market; modified from (Patel, 
2008; Wagner et al., 2006)  
Registered Trademark API 
Estrasorb® Estradiol 
Amphotec® Amphotericin B 
Abraxane® Paclitaxel 
Rapamune® Sirolimus 
Emend® Aprepitant 
 
 
In immunology vaccines are used to achieve adaptive immunity for various illnesses. 
Nanocarriers have been investigated as adjuvants formulations. Up to now, aluminium salts are 
the most common adjuvants used in current vaccine formulations. They are safe to use and they 
can generate an enlarged humoral immune response (Demento et al., 2009). Additional delivery 
carriers are necessary as many new antigens are only weakly immunogenic. A nano sized 
emulsion (MF59) is already approved for human use and on the market in Europe (Peek et al., 
2008). 
Polymeric nanoparticles have to meet strict requirement such as biocompatibility, 
biodegradability and compatibility with the antigen to be considered as vaccine formulations. 
PLGA is an FDA approved excipient that may be used to formulate nanoparticles that meet the 
necessary requirements (Drug Master File is registered with FDA) (Mitsui-Chemicals, 2010).  
Nanoparticles can act as adjuvants as they can enhance the uptake of antigens into cells and they 
can be used as controlled delivery systems, prolonging the availability of an antigen (Rice-Ficht 
et al., 2010).  
Nanoparticles are able to protect the drug of hostile environments like the conditions in the 
gastrointestinal tract. Nanoparticles can therefore improve the oral vaccination of proteins and 
peptides as they enhance their transmucosal transport (des Rieux et al., 2006). Mucosal 
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vaccination reduces the risk of infections at the injection site and has a better compliance. Further 
it is generally more cost efficient and makes large population immunization possible.  
Nevertheless, immunization through the parental route is also important, as most antigens cannot 
be delivered orally, even when using nanoparticles. Nanoparticulate delivery systems may play 
an important role in vaccine formulation in the future as they can specifically deliver antigen to 
antigen presenting cells like dendritic cells (Cruz et al., 2010). Targeting dendritic cells enhances 
the immune response and also makes lower dosage of the antigen possible, leading to reduced 
side effects. PLGA nanoparticles also have a great potential as adjuvants as they facilitate 
dendritic cell maturation (Akagi et al., 2012). 
Nanoparticles may also be used in immunotherapy to utilize the immune system in the treatment 
of cancer, which could lead to a prevention of the metastatic spread. Further, prophylactic cancer 
vaccines might be developed using nanoparticles as carriers to prevent cancer in the first place. 
Vaccines for hepatitis B and human papillomavirus are already being used to reduce the risk of 
liver cancer and cervical cancer, respectively (Hamdy et al., 2011).  
Nanoparticles have several benefits over microparticles for antigen delivery, because their 
smaller size leads to better uptake by dendritic cells, which in turn leads to a better immune 
response (Li et al., 2011). The significant larger surface area also allows nanoparticles to adsorb 
more antigen per weight as microparticles (Oyewumi et al., 2010). The particle size and the 
surface properties appear to be central in vaccine formulations using nanoparticles. Nanoparticles 
may also be used to co-deliver antigens and adjuvants (Rice-Ficht et al., 2010).  
FDA approved PLGA and its derivatives are common polymers for the preparation of polymeric 
nanoparticles (Drug Master File is registered with FDA) (Mitsui-Chemicals, 2010). Common 
nanoparticle preparation methods have already been established and include emulsification 
solvent evaporation method, emulsification solvent diffusion method, double-emulsion method, 
salting-out, nanoprecipitation method and ionic gelation (Bala et al., 2004; Pinto Reis et al., 
2006; Vauthier and Bouchemal, 2009).  
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2.3.1 Preparation of protein loaded nanoparticles 
Polymeric nanoparticles loaded with hydrophilic drugs such as proteins can be obtained by 
several preparation methods. Most common is the double-emulsion method. Adsorption of the 
protein on the nanoparticles following an emulsification solvent-evaporation method, a solvent 
displacement method and salting-out are also options to prepare protein loaded nanoparticles.  
In the double-emulsion method the protein is dissolved in an aqueous phase and emulsified with 
an oil phase containing a polymer. This primary water in oil emulsion is then emulsified with an 
outer water phase containing PVA as a stabilizer. Solvent-extraction using a high amount of 
water or solvent-evaporation under reduced pressure leads to the precipitation of nanoparticles 
containing the hydrophilic drug (Bilati et al., 2005). The particle size is dependent on a lot of 
variables, including the concentration of the hydrophilic drug in the inner water phase, the 
viscosity of the organic phase, the concentration of the stabilizer in the outer water phase, the 
emulsification conditions and the organic solvent removal method. Nanoparticles prepared by the 
double-emulsion method have been widely described and characterized in regard to their particle 
size, loading rate and dissolution kinetics (Lamprecht et al., 2000b), their potential for clinical 
application (Cheng et al., 2012) and their in-vivo effects (Gutierro et al., 2002b; Kasturi et al., 
2011). The morphology of the nanoparticles has been investigated using SEM (Giovino et al., 
2012; Khoee et al., 2012), FE-SEM (Sahana et al., 2010), atomic force microscopy (Lamprecht et 
al., 1999) and transmission electron microscopy (Cohen-Sela et al., 2009; He et al., 2004). These 
imaging techniques were used to determine the shape and to confirm the particle size of the 
prepared nanoparticles. However, the inner morphology of the nanoparticles could not be 
revealed.   
The emulsification solvent-evaporation method is a frequently used method to prepare polymeric 
nanoparticles. Briefly, the polymer is dissolved in an organic phase and afterwards emulsified in 
a water phase. This water phase usually contains a surfactant to stabilize the emulsion that is 
formed following the emulsification process. The organic solvent is removed from the emulsion 
under reduced pressure, leading to the formation of solid nanoparticles (Desgouilles et al., 2003). 
The protein is then adsorbed at the surface on the nanoparticles via incubation of the protein with 
the nanoparticles on a horizontal shaker. This method is advantageous as compared to the double-
emulsion method in that respect that it does not stress the protein during the emulsification 
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process and therefore reduces the problem of protein degradation and degeneration during the 
preparation. The particle size can be easily controlled by the surfactant concentration in the 
aqueous phase and the emulsification conditions.  
A modified solvent displacement method was described to obtain protein loaded nanoparticles 
using polyethylene glycol as a solvent for the polymer (Ali and Lamprecht, 2013). The solvent 
containing the polymer is mixed with an aqueous phase containing a protein and added to a 
disperse phase under magnetic stirring, causing the polymer-rich solvent phase to form 
nanodroplets. The polyethylene glycol is then extracted with water and protein loaded 
nanoparticles precipitate.  
The salting-out method is based on an aqueous phase that contains electrolytes and a stabilizer, 
e.g. PVA, forming an emulsion with an inner phase, e.g. acetone that contains the polymer and 
the drug. After homogenization the o/w-emulsion is diluted with water, which leads to a diffusion 
of acetone to the aqueous phase, which induces the formation of nanoparticles (Pinto Reis et al., 
2006). The encapsulation efficiency is dependent on the salting-out agent. Suitable electrolytes 
include magnesium chloride, calcium chloride and magnesium acetate. Even though the process 
is not as harsh as the double-emulsion method, proteins do not show high encapsulation rate, 
therefore the salting-out method is mainly used for lipophilic drugs.  
 
2.4 Microparticles 
Microparticles have a particle size of 1 µm – 1000 µm and a spherical morphology. They can be 
classified as microcapsules that have a polymeric shell and an API core, and microspheres, where 
the API is homogenously dispersed in the polymeric matrix (Mäder and Weidenauer, 2010; van 
de Weert et al., 2000) (Fig. 4). Polymeric microparticles can consist of a biodegradable and 
biocompatible polymer and an API. They can be used as parental drug delivery systems (Jain, 
2000), furthermore, oral delivery (Lamprecht et al., 2004), nasal delivery (Garmise et al., 2007) 
and pulmonary delivery (Fu et al., 2002) have been investigated. However, parental applications 
are used for the most part, as they cause a sustained release of an API for a prolonged period of 
time (Ye et al., 2010).  
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Fig. 4: Morphology of microparticles: a) Microcapsule with polymeric shell and solid or liquid 
API core; b) Microsphere with API dispersed in polymer matrix 
 
Many injectable microparticulate drug carriers are already on the market (Table 4), since 
microparticles offer many advantages compared to conventional dosage forms, e.g. the possibility 
of a controlled release of the API over a prolonged period of time (Faisant et al., 2006), no need 
for surgical removal, easy administration (Siepmann et al., 2004) and a better compliance due to 
the fact that the number of injections can be reduced. Microparticles can be used as drug delivery 
systems for a wide variety of therapeutics. Therefore, they have the potential to be used in many 
different fields, e.g. the antigen delivery (O’Hagan and Singh, 2003), cancer treatment (Allhenn 
et al., 2013) and as antipsychotics (Bobo and Shelton, 2010). 
 
Table 4: Selection of injectable microparticulate drug carriers on the market (Mäder and 
Weidenauer, 2010; Mundargi et al., 2008) 
Registered Trademark API Preparation Technique 
Decapeptyl® SR Triptorelin Phase separation 
Lupron Depot® Leuprorelin Emulsion method 
Suprecur® MP Buserelin Spray drying 
Sandostatin® LAR® Octreotide Phase separation, Spray drying 
Risperdal® Consta® Risperidon Emulsion method 
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Biodegradable and biocompatible polymers like PLGA are the excipients of choice for the 
particulate delivery of antigens via microparticles. PLGA microparticles are proven to be safe to 
use in humans and are very promising systems that present multiple copies of the antigen to the 
immune system (Wendorf et al., 2008).  
In vaccine research particulate formulations such as microparticles are generally used as vaccine 
delivery systems to target antigens into antigen-presenting cells. However, microparticles can 
also be used as delivery systems for adjuvants to increase their immunostimulatory effect. A 
controlled release of the adjuvant causes a reduced toxicity and limits the systemic distribution of 
the adjuvant, which could reduce adverse effects (O’Hagan and Singh, 2003). 
Particulate carriers like microparticles are able to be internalized by antigen presenting cells and 
macrophages, since they are of similar size as many pathogens (O’Hagan et al., 2006). Therefore, 
they can increase the amount of antigen that reaches the intracellular space, which could lead to a 
higher efficiency of the vaccine formulation.  
Injectable microparticles have the potential to act as single-dose vaccines, combining the initial 
immunization with a booster vaccination. Therefore a higher compliance could be achieved and 
costs could be lowered significantly. Ideally, an initial burst release of the antigen is followed by 
a “lag time”, in which no antigen is released. The release can be tailored with different polymeric 
types. Pulse releases of the antigen after several weeks to provide booster responses are desired 
(Singh et al., 2007). However, a benefit of pulse releases has not been proven yet in vivo.  
Microparticles might also be used for oral immunization and offer advantageous like a better 
compliance, less side effects and easier administration. Microparticles have the ability to be taken 
up by mucosal-associated lymphoid tissue, which is crucial for the delivery of the antigen to the 
lymphoid tissue. Another promising immunization route is the intranasal route as the 
environment for the antigen is better, since there are less proteolytic enzymes and a less acidic pH 
(Gutierro et al., 2002a). 
A key issue in the antigen delivery with microparticles remains the stability of the antigen. Due 
to the conditions in the particle and during the encapsulation process, aggregation and 
denaturation might reduce the immunogenicity of the antigen (Caputo et al., 2008). To avoid this 
problem, surface adsorbed proteins that can easily be released from the surface might be a 
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promising alternative. Another approach is the adsorbtion of DNA onto the surface of cationic 
microparticles. Like for surface adsorbed proteins, this technique reduces the high stress the API 
is submitted to during the particle preparation (Singh et al., 2004).  
A few immunization studies in vivo in mice and pigs were performed using mostly PLGA 
microspheres. Particle sizes of ≤ 10 µm were favorable to bigger particles in regard to their 
immune response, however the effect of microparticulate vaccine formulations has not been 
tested in humans, yet (Gutierro et al., 2002a; Heegaard et al., 2011; O’Hagan et al., 2006; 
Waeckerle-Men and Groettrup, 2005).  
 
There are a number of manufacturing techniques to prepare microparticles. Depending on the 
API and the intended release profile a suitable preparation method must be chosen. 
Microencapsulation methods include phase separation, spray drying, emulsion methods, 
electrospray method, microfluidic methods and micro fabrication methods (Ye et al., 2010).  
The phase separation yields mainly microcapsules. A polymer is dissolved in an organic solution 
and the API is dispersed in the polymer solution. For each API a proper polymer with suitable 
interface characteristics must be selected. An organic non-solvent that does not dissolve either the 
polymer or the drug and is miscible with the polymer solvent is added. Phase separation sets in 
and the polymer accumulates around the API, leading to coacervate droplets. Using solvent 
extraction the microdroplets are formed to microparticles (Jalil and Nixon, 1990). 
A one step and continous process to obtain microparticles is spray drying. The scale up is 
manageable, the method is very rapid and the solubility of the API and the polymer are less 
crucial, compared to phase separation and emulsion methods (Takada et al., 1995; Wagenaar and 
Müller, 1994). A liquid is dispersed from a spray nozzle and the suspension or solution separates 
as solid and the solvent evaporates. When using suitable nozzles, microparticles can be prepared. 
Another method is spray freeze drying, where the liquid is sprayed into liquid nitrogen and the 
frozen droplets are later freeze dried (Eggerstedt et al., 2012). This is especially advantageous for 
thermo labile APIs. 
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Common techniques to prepare polymeric microparticles containing polyesters for the application 
as implants or injectable, parental drug delivery systems are emulsion methods. With a single 
emulsion process and a subsequent solvent evaporation or solvent extraction process, particles 
can be formed. A polymer and a drug are dissolved in an organic solvent that is immiscible with 
water. The organic phase is then emulsified with water containing a surfactant, e.g. PVA. The 
organic solvent is then removed by adding huge quantities of water and therefore extracting the 
organic solvent or by evaporating the organic solvent under reduced pressure (Arshady, 1991). 
The microparticle suspension can be filtrated and dried under appropriate conditions to obtain an 
injectable product (Jain, 2000). When using o/w-emulsions water soluble drugs diffuse into the 
aqueous phase, leading to poor encapsulation rates. Hence, this method is more frequently used 
for lipid-soluble APIs. Encapsulation of water soluble drugs can be obtained by using an oil-in-
oil (o/o)-emulsion method, in which a water miscible organic solvent is used. It must be able to 
dissolve the drug and the polymer. As an outer phase a mineral oil is used, after emulsification 
and evaporation microparticles are formed containing the API. To wash off the mineral oil, 
another organic solvent, e.g. n-hexane, is used.  
Due to the use of a lot of toxic solvents, other methods to encapsulate hydrophilic drugs are 
preferable. An alternative to the emulsion methods using methylene chloride or other toxic 
organic solvents is the preparation of microparticles using glycofurol as a solvent (Allhenn and 
Lamprecht, 2011). The double-emulsion method is best suited to encapsulate hydrophilic drugs. 
 
2.4.1 Preparation of protein loaded microparticles 
Polymers containing proteins as a sustained release formulation have been investigated since 
1976 (Langer and Folkman, 1976). The preparation of biodegradable and biocompatible 
microparticles containing proteins as an API have various advantages compared to traditional 
dosage forms, which include reduced toxicity, improved compliance and a controlled-release 
drug delivery system (Luan et al., 2006; Meng et al., 2003).  
Manufacturing of protein loaded microparticles can be achieved with multiple methods. Spray 
drying and spray freeze drying are suitable options, however they require expensive and complex 
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manufacturing processes. A common method to prepare protein loaded microparticles in the 
laboratory scale is the w/o/w-double-emulsion method (Coombes et al., 1998; Crotts and Park, 
1998). This technique has been further developed and w/o/o-, s/o/w-, s/o/o, s/o/o/w-emulsion 
methods (Paillard-Giteau et al., 2010; Ye et al., 2010; Yuan et al., 2009) are potential ways to 
encapsulate proteins.  
The double emulsion technique starts with dissolving a suitable polymer, e.g. PLGA, cellulose or 
polylactide in an organic solvent, e.g. ethyl acetate or methylene chloride (Porjazoska et al., 
2004). Then a protein is dissolved in water and emulsified in the organic phase, forming a water-
in-oil emulsion. This emulsion is commonly referred to as the primary emulsion (Sah, 1999). 
After this first emulsification step the primary emulsion is dispersed in an outer aqueous phase 
containing a stabilizer, e.g. PVA. During this second emulsification step a w/o/w-double 
emulsion is formed (Jain, 2000). To remove the organic solvent a solvent extraction or a solvent 
evaporation method can be applied. For the solvent extraction method the double emulsion is 
introduced into a high volume of water. The organic solvent is thereby extracted from the double 
emulsion and then, under continuous stirring of the formulation, evaporates at room temperature. 
For the solvent evaporation method the organic solvent of the double emulsion is removed by 
evaporation under reduced pressure using a rotary evaporator (Uchida et al., 1995). The resulting 
microparticle suspension can then be centrifuged or filtrated to obtain the particles.  
PLGA is a commonly used polymer for this method, since it is not soluble in water. It also has 
major advantages compared to other polymers, because it is a safe to use FDA approved 
excipient that is biodegradable and biocompatible. The double emulsion technique is easy to 
handle and offers relatively mild conditions for the protein. However, the double emulsion 
method also faces a lot of challenges, e.g. instability of the encapsulated protein, an incomplete 
release of the protein and loss of the protein during the encapsulation process (Putney and Burke, 
1998; Yeo and Park, 2004). Due to the acidic environment in PLGA hydrolysis of peptide bonds 
of the protein has been observed (Jiang et al., 2005). Modifications of the protein, like the 
hydrolysis of peptide bonds or changes in the tertiary structure through aggregation or 
denaturation, can lead to a loss of functionality of the protein (Schwendeman, 2002). During the 
double emulsion method the protein is confronted with several conditions that could lead to 
protein denaturation. During the emulsification steps, the protein may be submitted to heat or 
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shear forces. Cooling can be beneficial to maintain protein stability. The protein is exposed to an 
organic surface during the preparation process, which can lead to aggregation of the proteins 
(Sah, 1999).  
2.5 In vivo immunization studies  
The immune system of a mammal is too complex to be sufficiently simulated in cell culture 
experiments. The effect of an antigen and an adjuvant on the immune response can only be 
adequately determined by an in vivo vaccination study.  
Mice are commonly used in immunization studies, as they can be easily handled in a laboratory 
scale. Ovalbumin can act as a model antigen that provokes antibody response in mice (Kasturi et 
al., 2011). The potency of this response can be used to compare and to evaluate different 
adjuvants that are administered in combination with the antigen. In general, two injections three 
to four weeks apart from one another of the antigen are given to the test animal. Blood samples 
are usually drawn before the first injection to confirm that no antibodies for the given antigen are 
present in the beginning of the experiment. Furthermore, five to seven weeks after the first 
injection blood samples are drawn to evaluate the antibody titers after two injections of the 
antigen (Gutierro et al., 2002b; TVT, 2010). For immunization purposes, intravenous, 
subcutaneous, intramuscular, intradermal or intraperitoneal injections are established parental 
delivery routes for vaccines in mice (Mohanan et al., 2010; TVT, 2010). 
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3 Materials and Methods 
 
3.1 Substances 
3.1.1 Poly(lactic-co-glycolic acid) (PLGA) 
The PLGA copolymers (Table 5) were kindly provided by Boehringer Ingelheim (Ingelheim, 
Germany) and Evonik (Essen, Germany). PLGA (Fig. 5) is synthesized by ring-opening 
copolymerization of two different monomers, the cyclic dimers (1,4-dioxane-2,5-diones) of 
glycolic acid and lactic acid. Common catalysts used for this reaction include tin(II) 2-
ethylhexanoate, tin(II) alkoxides or aluminum isopropoxide (Lu et al., 2009; Mäder and 
Weidenauer, 2010). PLGA is a FDA approved excipient (Drug Master File is registered with 
FDA) (Ji et al., 2012), which is biocompatible and biodegradable (Anderson and Shive, 1997).  
 
Table 5: Polymers used to prepare microparticles and nanoparticles 
Trademark End group Composition 
RG 502 H Acid Poly(D,L-lactide-co-glycolide) 50:50 
RG 503 H Acid Poly(D,L-lactide-co-glycolide) 50:50 
RG 504 H Acid Poly(D,L-lactide-co-glycolide) 50:50 
RG 505  Ester Poly(D,L-lactide-co-glycolide) 50:50 
 
 
The glass transition temperature of the PLGA copolymers is above 37 °C and the biodegradation 
occurs by non-enzymatic hydrolysis of the ester backbone (Jain, 2000; Yoo et al., 2005). Each 
polymer that was used to prepare micro- and nanoparticles has a composition of equal amounts of 
lactic acid and glycolic acid and they degrade in approximately one to two months in vitro (Nair 
and Laurencin, 2007).  
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Fig. 5: Chemical structure of PLGA (x = number of units of lactic acid, y = number of units of 
glycolic acid) 
 
3.1.2 Bovine Serum Albumin (BSA) 
BSA was purchased from Sigma Aldrich (Munich, Germany). BSA consists of 583 amino acids 
and has a molecular weight of 66.4 kDa (Hirayama et al., 1990). The isoelectric point is 4.7 (Ge 
et al., 1998). BSA was used as a model protein for the development of different micro- and 
nanoparticle formulations. It has already been widely used as a model protein for the preparation 
of micro- and nanoparticles due to its stability (Lamprecht et al., 2000b) and low cost. For studies 
with the FE-SEM BSA was substituted with Gold-BSA (Aurion®, Netherlands) as the 
hydrophilic compound due to its characteristics to be visible under the FE-SEM.  
 
3.1.3 Ovalbumin (OVA) 
OVA was obtained from Sigma Aldrich (Munich, Germany). OVA has a molecular weight of 
45 kDa, consists of 386 amino acids (Huntington and Stein, 2001; Nisbet et al., 1981), and has an 
isoelectric point of 4.86 (Smith, 1935). OVA is the major protein in avian egg-white (60-65%), 
however its function is unknown (Huntington and Stein, 2001). Nevertheless, OVA has been 
used as a model antigen in many vaccine studies (Kasturi et al., 2011; Singh et al., 2007; Uchida 
et al., 1995), since it is a safe to use and well characterized immunogen. Here, we used OVA as a 
model protein for formulation experiments with nanoparticles and as a model antigen for in-vivo 
studies with mice.  
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3.1.4 Lysozyme 
Lysozyme was kindly provided by Boehringer Ingelheim Vetmedica GmbH (Ingelheim, 
Germany). Lysozyme is obtained from hen egg white. It consists of 129 amino acids and has a 
molecular weight of 14.3 kDa (Blake et al., 1965; Canfield, 1963). It has an isoelectric point of 
11.35 (Wetter and Deutsch, 1951). Lysozymes are enzymes that catalyze the hydrolysis of β-1,4 
glycosidic bonds between N-acetylmuramic acid and N-acetly-D-glucosamine residues in 
peptidoglycans. Peptidoglycans can be found in bacteria, especially in Gram positive bacteria. 
Therefore, lysozymes have antibacterial properties and are part of the immune system (McKenzie 
and White, 1991). In this work lysozyme was used as a model antigen for a small protein with a 
basic isoelectric point in various nanoparticle formulation studies. 
 
3.1.5 α-toxin 
Clostridium perfringens is a Gram-positive anaerobe pathogen that causes gas gangrene (Leslie et 
al., 1989; Titball, 2009) . Every Clostridium perfringens strain possess the gene encoding α-toxin 
(Titball et al., 1999). Formaldehyde α-toxins have already been used as experimental vaccines in 
humans and toxoid vaccines for sheep and goats are commercially available (Titball, 2005). 
Two different C. perfringens α-toxoid antigens were kindly provided by Boehringer Ingelheim 
(Hannover, Germany). One antigen is α-toxoid derived from C. perfringens cell culture, the other 
antigen is E.coli derived α-toxoid. The Clostridium perfringens derived α-toxoid was inactivated 
with formaldehyde and neutralized with sodium bisulfite. E.coli express mutated which is 
therefore already inactived α-toxoid. Both antigens were used for nanoparticle formulation 
experiments, as results are more likely to be applicable to other recombinant proteins. α-Toxin 
has a molecular weight of 43 kDa (Leslie et al., 1989).  
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3.1.6 Carbopol 
Carbopol was kindly provided by Boehringer Ingelheim (BIV Inc., St. Joseph, USA). Carbopol is 
a cross-linked polyanionic carbomer (Rachel et al., 2012) which is used as an adjuvant in in-vivo 
studies in this work. Carbopol has shown the property to increase the antibody response for 
veterinary vaccines, while also being well tolerated (Dey et al., 2012).  
 
3.1.7 Emulsigen D 
Emulsigen D was purchased from MVP Laboratories (Omaha, USA). Emulsigen D is an oil-in-
water emulsified adjuvant combined with dimethyldioctadecylammonium bromide (DDA) as an 
immunostimulant (Hiszczyńska-Sawicka et al., 2010). Here, it was used for stabilization and 
formulation studies with protein loaded nanoparticles. 
 
3.1.8 Lipopolysaccharides (LPS) 
LPS is a component of the cell wall of Gram-negative bacteria. LPS consists of three parts, a 
hydrophobic lipid (lipid A), a polysaccharide chain as the hydrophilic core and a hydrophilic O-
antigenic polysaccharide side chain (Sigma-Aldrich, 2013c). LPS stimulates cells of the innate 
immune system by Toll-like receptor 4 (TLR4) (Demento et al., 2009). 
Lipopolysaccharides from salmonella enterica serotype abortus equi (LPS) and fluorescein 
isothiocyanate labeled lipopolysaccharide (FITC-LPS) were obtained from Sigma Aldrich 
(Munich, Germany). LPS was used to formulate PLGA-nanoparticles with surface adsorbed LPS 
(LPS-NP). These nanoparticles were used as adjuvants in in-vivo studies for this work. LPS was 
substituted with FITC-LPS to quantify the amount of LPS that was adsorbed on the particles.  
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3.1.9 Freund’s Adjuvant 
Freund’s Adjuvant (CFA) and Incomplete Freund’s Adjuvant (IFA) were purchased from Sigma 
Aldrich (Munich, Germany). CFA is an emulsion that consists of heat killed and dried 
Mycobacterium tuberculosis, paraffin oil and mannide monooleate as the outer oil phase. The 
inner water phase contains the antigen, in this case OVA (Sigma-Aldrich, 2013b). IFA consists of 
paraffin oil and mannide monooleate and lacks the bacteria. It also forms an emulsion with an 
inner water phase, which contains the antigen (Williams and Mahaguna, 1998). For in-vivo study 
III in this work CFA and IFA were used as adjuvants. They were prepared by adding 2.5 ml of 
the oil phase to 2.5 ml of the water phase containing 0.01% OVA in PBS. The emulsion was 
formed by using an Ultra turrax® (T 10 basic Ultra turrax®, IKA®, Staufen, Germany) at 
10000 rpm for 4 minutes. The resulting thick emulsion was tested by placing one drop of the 
emulsion on the surface of PBS. The drop of the emulsion was not allowed to disperse; if the 
drop disperses on the surface of PBS the emulsion is not stable and not suitable for injection.  
  
3.1.10 Polyvinyl alcohol (PVA) 
Polyvinyl alcohol (PVA) (Mowiol® 4-88, Kuraray Europe GmbH, Germany) (Fig. 49) was a gift 
from Kuraray Europe GmbH. PVA is a synthetic and water soluble polymer. After 
polymerization of vinyl acetate to polyvinyl acetate the hydrolysis of polyvinyl acetate results in 
PVA (Marvel and Denoon, 1938). PVA was used as a stabilizer in the outer water phase for the 
preparation of micro- and nanoparticles with the double emulsion method. It was also used as a 
surfactant for the preparation of nanoparticles with the o/w-emulsification-evaporation-method. 
 
3.1.11 Polysorbate 20 
Polysorbate 20 (Tween® 20) was purchased from Carl Roth® (Karlsruhe, Germany). Tween 20 
(Fig. 50) is a polyoxyethylene sorbitan ester and has a molecular weight of 1225 g/mol. Tween 
20 is a nonionic surfactant with a critical micelle concentration (CMC) of approximately 
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0.05 mmol/l (Zhu et al., 2011). It was used as a surfactant for the preparation of nanoparticles 
with the o/w-emulsification-evaporation-method. 
 
3.1.12 Sodium dodecyl sulfate (SDS) 
Sodium dodecyl sulfate (SDS) (Fig. 51) was obtained from Sigma Aldrich (Munich, Germany): 
SDS is an anionic surfactant with a molecular weight of 288 g/mol and a CMC of 8 mmol/l 
(Fuguet et al., 2005). It was used as a surfactant for the preparation of nanoparticles with the o/w-
emulsification-evaporation-method and to linearize proteins in the polyacrylamide gel 
electrophoresis (SDS-PAGE). 
 
3.1.13 Sodium cholate 
Sodium cholate (Fig. 52) was purchased from Sigma Aldrich (Munich, Germany). Sodium 
cholate is an anionic surfactant with a molecular weight of 431 g/mol and a CMC of 
approximately 12 mmol/l (Sigma-Aldrich, 2013a). It was used as a surfactant for the preparation 
of nanoparticles with the o/w-emulsification-evaporation-method.  
 
3.1.14  Cetyltrimethylammonium bromide (CTAB) 
Cetyltrimethylammonium bromide (CTAB) (Fig. 53) was purchased from Carl Roth® 
(Karlsruhe, Germany). CTAB is a cationic surfactant with a molecular weight of 364 g/mol and a 
CMC of approximately 0.9 mmol/l (Zdziennicka et al., 2012).It was used as a surfactant for the 
preparation of nanoparticles with the o/w-emulsification-evaporation-method. 
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3.1.15  Nile red 
Nile red was purchased from Sigma Aldrich (Munich, Germany). Nile red has a molecular weight 
of 318 g/mol. It is a lipohilic fluorescent stain that has an excitation wavelength of 544 nm and 
that emits at 615 nm in ethanol (Greenspan et al., 1985). Nile red was used to stain nanoparticles 
that were further used in cell culture experiments. 
 
3.1.16  Dithiothreitol (DTT) 
Dithiothreitol (DTT) was obtained from Carl Roth® (Karlsruhe, Germany). It has a molecular 
weight of 154 g/mol. DTT is a reducing agent. It was used in combination with SDS for 
quantification of adsorbed protein. DTT reduces disulfide bonds of the protein and SDS 
linearizes the protein (Wu and Narsimhan, 2008). Furthermore, SDS causes the protein to desorb 
from the particle surface as it replaces the protein on the surface (Crotts and Park, 1997). 
 
3.2 Oil-in-water-emulsification-evaporation method 
Biodegradable polymers, such as PLGA, can be used to prepare polymeric nanoparticles (Gurny 
et al., 1981). For the purpose of preparing protein loaded nanoparticles an oil-in-water-
emulsification-evaporation-method (Fig. 6) was used as previously described (Vauthier and 
Bouchemal, 2009; Wachsmann and Lamprecht, 2012). First an oil-in-water emulsion was 
formed. PLGA (20 mg/ml- 100 mg/ml) dissolved in ethyl acetate acted as the oil phase. The outer 
water phase contained a surfactant (Table 6). 
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Fig. 6: Schematic presentation of nanoparticle preparation using an oil-in-water emulsification 
evaporation method 
 
The organic phase was emulsified with the outer water phase by ultrasound using a Sonopuls HD 
2200 sonicator (Bandelin electronic, Germany). The organic solvent of the resulting o/w-
emulsion was then removed using a rotary evaporator at 45 °C under reduced pressure. The water 
insoluble PLGA precipitated as nanoparticles (o/w-NP).  
 
 
Table 6: Surfactants used for the preparation of polymeric nanoparticles loaded with proteins 
Surfactant Concentration [g/100 ml] 
PVA 1; 0.3; 0.1 
Tween 20 1; 0.3; 0.1 
Sodium cholate 0.1; 0.05; 0.01 
SDS 0.1; 0.05; 0.01 
CTAB 0.1; 0.05; 0.03; 0.01 
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3.2.1 Preparation of nanoparticles with adsorbed proteins 
Polymeric nanoparticles that were prepared as described previously (3.2) were incubated with a 
protein solution (BSA, OVA or Lysozyme) in various concentrations (0.1 mg/ml – 2 mg/ml) for 
3 hours on a horizontal shaker (Edmund Bühler, Tübingen, Germany). Nanoparticles that were 
incubated with α-toxin were freeze-dried (see section 3.4) before incubation with the protein 
solution. 
 
3.2.2 Preparation of LPS loaded nanoparticles 
LPS loaded polymeric particles were prepared by an oil-in-water-emulsification-evaporation-
method as described above (see section 3.2). PLGA (10 mg/ml) dissolved in ethyl acetate acted 
as the oil phase. LPS (1 mg/ml) was used in the outer water phase and no surfactant was 
necessary for the preparation of nanoparticles.  
 
3.3 Water-in-oil-in-water double emulsion method 
For the preparation of protein loaded micro- and nanoparticles a double-emulsion method (Fig. 7) 
was performed as previously described (Buske et al., 2012; Cho and Sah, 2005; Okada et al., 
1988). Briefly, the protein was dissolved in PBS (w1-phase) and emulsified in an organic solvent 
containing dissolved PLGA (o-phase). This water-in-oil (w1/o) primary emulsion was emulsified 
into the outer water phase (w2) containing PVA as a stabilizer and a water-in-oil-in-water double-
emulsion is formed (w1/o/w2). The organic solvent was removed by extraction (solvent extraction 
method) with water and evaporation of the organic solvent at room temperature or the organic 
solvent was removed by using a rotary evaporator (solvent evaporation method). The 
precipitating particles were then either filtrated using a cellulose acetate membrane filter (2.7 µm, 
Whatman, United Kingdom) or centrifuged using a Hermle Z 233 M-2 (Hermle Labortechnik, 
Wehingen, Germany) at 19000 rpm for 20 min. and dried overnight in an exsiccator.  
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Fig. 7: Scheme of double emulsion method 
 
3.3.1 Preparation of protein loaded microparticles 
PLGA microparticles were prepared by a double emulsion method as described above (see 3.3). 
BSA dissolved in PBS (w1) was used as a model protein (10 mg/ml). PLGA in various 
concentrations was dissolved in ethyl acetate (33.3 mg/ml - 83.3 mg/ml) and the primary 
emulsion was generated by using ultrasonication or an Ultra turrax® (T 10 basic Ultra turrax® or 
T 18 Ultra turrax®, IKA®, Staufen, Germany) at varying speeds for 30 seconds. The w1/o-
emulsion was emulsified in PVA (0.1% - 1% (m/V)) using a propeller stirrer (IKA® RW 20 
digital, IKA®, Staufen, Germany) at varying speeds (500 rpm - 1000 rpm) for 2 minutes. Then, 
water was used to extract ethyl acetate and the formulation was stirred for 2 h to evaporate the 
organic solvent. The resulting microparticle suspension was then filtrated and dried overnight in 
an exsiccator. 
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3.3.2 Preparation of protein loaded nanoparticles 
PLGA nanoparticles (w/o/w-NP) were prepared by a double emulsion technique (Fig. 7) (Blanco 
and Alonso, 1997; Lamprecht et al., 1999; Zambaux et al., 1998). BSA dissolved in PBS (w1) 
was used as a model protein (10 mg/ml). PLGA was dissolved in ethyl acetate or methylene 
chloride (33.3 mg/ml) and the primary emulsion was generated by using a Sonopuls HD 2200 
sonicator (Bandelin electronic, Germany) for 90 seconds. The w1/o-emulsion was emulsified in 
PVA (0.1%-5% (m/V)) using ultrasonication for 60 seconds. The organic solvent was removed 
under reduced pressure at 45 °C for 20 minutes which led to the precipitation of nanoparticles 
(w/o/w-NP). For imaging studies of the cross-section of the nanoparticles (see 3.5.7) BSA was 
substituted with Gold-BSA. 
 
3.4 Freeze drying of nanoparticles 
For stability studies of the nanoparticles that were loaded with the α-toxin, nanoparticles were 
freeze dried using a Lyovac® GT2 (Steris, Germany). Trehalose (5% (m/V)) was added to the 
nanoparticle formulation as a cryoprotectant. 
3.5 Analytical methods 
3.5.1 Particle size analysis 
3.5.1.1 Photon Correlation Spectroscopy (PCS) 
Particle size and polydispersity index (PDI) of nanoparticles were determined by photon-
correlation spectroscopy (PCS) using a ZetaPlus particle sizer (Brookhaven Instruments 
Corporation, UK) at a fixed angle of 90 ° at 25 °C. 100 µl of the nanoparticle sample was diluted 
with water in a UV-Cuvette macro (Brand GmbH, Germany). Each sample was measured in 
triplicates. Each measurement consisted of 5 runs with a duration of 1 min. each. The analysis 
was done using the Brookhaven Instruments Particle Sizing Software Version 3.88.  
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3.5.1.2 Laser diffraction 
The particle size and the particle size distribution of microparticles were determined by laser 
diffraction analysis using a Helos 12 KA/ LA (Sympatec, Clausthal-Zellerfeld, Germany) 
equipped with a helium-neon laser. The measurement is based on the concept that particles of a 
certain size diffract light through a given angle and intensity. The angle increases when the 
particle size decreases (McCave et al., 1986), and the intensity increases when the particle size 
increases. The diffraction pattern is detected and the particle size distribution can be generated. 
The analysis was performed with the Windox Software Version 3.4 (Sympatec, Clausthal-
Zellerfeld, Germany) and the measured laser diffraction pattern was evaluated by the Fraunhofer 
diffraction model. Briefly, 10 mg of dried microparticle sample was suspended in 40 ml 0.2% 
Polysorbate 80 and aggregates were separated using ultrasonication. One ml of the suspended 
sample was deposited into a glass cuvette containing 40 ml of an aqueous 0.2 % Polysorbate 80 
solution and a magnetic stirrer that operated at 50%. Each sample was measured in triplicates. 
 
3.5.2 Encapsulation/loading-rate of protein 
The loading rate of the o/w-NP and w/o/w-NP with the model proteins BSA and OVA was 
determined using a BCA-Assay. The NP-samples were centrifuged at 19000 rcf for 15 minutes 
and the supernatant was collected and measured by a BCA-Assay. Thus, an indirect 
quantification of the protein content was performed. The encapsulation rate of the microparticle 
samples were also measured indirectly. After filtration of the obtained microparticle suspension, 
the protein content of the filtrate was investigated using a BCA-Assay. The loading rate of the 
o/w-NP with the α-toxin was handled as the o/w-NP samples with BSA and OVA. However, the 
supernatant was not examined by BCA-Assay, but SDS-PAGE gel electrophoresis (see 3.5.2.2). 
 
3.5.2.1 BCA-Assay 
Protein contents of the micro- and nanoparticle samples were measured by a BCA-Assay (Roti-
quant universal assay, Carl Roth®, Germany). Cu2+ ions are being reduced to Cu1+ ions by 
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protein bonds (Lowry et al., 1951). The principle of the BCA-Assay is that bicinchoninic acid 
forms an intense purple complex with cuprous ions (Cu1+) in alkaline environment (Smith et al., 
1985). 100 µl of the samples and standards were placed in a 96-well plate (PerkinElmer, 
Waltham, USA) and mixed with 100 µl of reagent solution of the BCA-Assay Kit. After 
incubation at 37 °C for 30 minutes the absorbance was measured at 490 nm using a plate reader 
(1420 Multilabel Counter Victor3 V, PerkinElmer, USA). 
 
3.5.2.2 SDS-PAGE gel electrophoresis 
To quantify the α-toxin content on the o/w-NP a SDS-polyacrylamide gel electrophoresis 
(PAGE) was performed. SDS-PAGE is widely used to separate proteins according to their 
molecular weight (Laemmli, 1970; Schagger and von Jagow, 1987). The samples were mixed 
with “Laemmli-buffer” containing SDS to linearize the protein and additionally to apply a 
negative charge to each protein. The buffer also contained glycerol to increase the density of the 
sample and Bromphenol blue as a tracking dye. The sample was further heated to 95 °C for 
5 minutes using a heating block (Thermomixer® comfort, Eppendorf®, Germany) and 2-
mercaptoethanol was added to reduce disulfide linkages. SDS-PAGE was performed using a 
MINI-PROTEAN®-system (Bio-Rad Laboratories, USA). The self-prepared separating gels had 
an acrylamide content of 12% and the stacking gels had an acrylamide content of 4%. 
Polymerization was initiated by adding ammonium persulfate and tetramethylethylenediamine. 
After adding the samples to the gels an electric field was applied, which led to the negatively 
charged proteins migrating to the positive electrode (anode). The gel was run for 2 h at 20 mA. 
The gels were then stained with Coomassie Brilliant Blue for 8 h and bleached with water, 
methanol and acetic acid afterwards. To calculate the protein content, α-toxin samples with a 
known concentration were used as a standard. Further a marker (Roti®-Mark Standard, Carl 
Roth®, Germany) was used to estimate the molecular weight of the separated proteins. To 
quantify the α-toxin content the stained gels were placed on a reflecta® L 300 light panel (Intas 
Science Imaging Instruments GmbH, Göttingen, Germany) and photographed with an Intas® 
camera system (Intas Science Imaging Instruments GmbH, Göttingen, Germany) and then a 
densitometric analysis was put out with ImageJ analysis system.  
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3.5.3 Release test 
The in-vitro dissolution tests were all carried out in PBS. A defined amount of the dried 
microparticle sample was suspended in a conical flask with PBS. The conical flask was incubated 
in a shaking water bath (GFL, Burgwedel, Germany) at 37 °C at 80 rpm. Samples were 
withdrawn at various times for the analyses of drug release. The protein content was determined 
as described above. The in-vitro dissolution tests of the nanoparticle samples were carried out in 
Eppendorf cups. 100 µl of nanoparticle suspension was mixed with 900 µl of PBS. Samples were 
withdrawn at various times for the analyses of drug release. The protein content was determined 
as described above. 
 
3.5.4 Zeta potential 
The measurement of the zeta potential was carried out using a ZetaPlus particle sizer 
(Brookhaven Instruments Corporation, UK). The analysis was done using the Brookhaven 
Instruments Zeta Potential Analyzer Software Version 3.54. 
 
3.5.5 Drop shape analysis 
The surface tension of protein and surfactant samples was measured using an Easy Drop FM 40 
(Krüss, Hamburg, Germany).  
After the samples were dissolved in various concentrations in water, a drop was formed using a 
syringe. This drop was further visualized with the camera of the Easy Drop FM 40. Using the 
Drop Shape Analysis Software (Krüss, Hamburg, Germany) the surface tensions was determined 
by the Young-Laplace-Equation (Eq. 1) (Lin et al., 1995). The “pendant drop method” was 
applied to measure the samples. For the measurement of interfacial tensions between methylene 
chloride and a water phase containing various samples the drop was injected into a glass vial 
containing methylene chloride.  
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Eq. 1: p = Laplace pressure 
 σ = surface tension 
 r1 = radius of curvature r1 
 r2 = radius of curvature r2 
 
 
3.5.6 Scanning electron microscopy (SEM) 
To investigate the morphology of micro- and nanoparticles SEM was used. The images were also 
used to confirm the findings regarding the particle size of micro- and nanoparticles. Before 
examining the sample in the SEM, a thin layer of gold was coated on the sample to prevent 
electrostatic charge at the surface (Rein, 2010). The samples in this work were attached to the 
sample carrier with double adhesive tape. Therefore, dried microparticles were simply put on the 
double adhesive tape. However, for the nanoparticle samples, one drop of the nanoparticle 
suspension was put on a cover slip and dried overnight. Afterwards, the cover slip was put on the 
double adhesive tape. Then the samples were coated with gold using a Polaron Sputter Coater 
(SC 7640, Quorum Technologies Ltd., UK) for 6 min. (microparticles) or 2 min. (nanoparticles). 
Afterwards, the samples were fixed at a sample table and put into the SEM (S 2460 N, Hitachi, 
Japan). The samples were investigated at various magnifications at 15 kV acceleration voltage, 
using a secondary electron detector.  
 
3.5.7 Field emission-scanning electron microscopy (FE-SEM) coupled with 
ion milling 
The FE-SEM was used to investigate the morphology of nanoparticles. The experiments were 
conducted at the Hitachi facility in Krefeld. The preceding ion milling was used to cut the 
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nanoparticles with an ion beam to examine the interior morphology afterwards in the FE-SEM. 
Due to the high accelerating voltages used in SEM, the specimen can be damaged (Jongebloed et 
al., 1999). Furthermore, charging of the specimen increases with high accelerating voltages (Kim 
et al., 1992). The FE-SEM produces images using very low accelerating voltages (≤ 5kV). 
Coating therefore becomes unnecessary, because the conductivity of the specimen is less 
important (Dunnebier et al., 1995) and less beam induced damage can be observed (Kim et al., 
1992). The electrons were emitted by a field emission electron gun. In this work a cold field 
emission source as a cathode was used. Here, we analyzed the w/o/w-NP with a SU8030 
(Hitachi, Tokyo, Japan) after ion milling with an IM4000 (Hitachi, Tokyo, Japan). One drop of 
the w/o/w-NP sample was put on a silicium plate and dried overnight. The silicium plate was 
then scratched with a diamond scriber and fractured in several pieces. A piece with a beveled 
edge was put in the IM4000 with the sample facing downwards and a mask on top of the silicium 
plate (Fig. 8). The IM4000 was then cooled down with liquid nitrogen to  -100 °C. Afterwards an 
argon beam (4 keV) cut the sample for 40 min. at an ion current of 140 µA. The sample was then 
recovered from the ion milling machine and investigated in the FE-SEM at 0.5-1 kV using 
various magnifications. A secondary electron detector, a low angle backscattered electron 
detector or a combination of the two detectors was used to visualize the signals emitted by the 
sample. 
 
 
Fig. 8: Schematic layout of ion milling process 
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3.5.8 Confocal laser scanning microscopy (CLSM) 
Using CLSM images of specimens at selected depths can be acquired, making it possible to 
visualize interior structures (Nikon, 2014). By using different fluorescent labels multiple 
compounds can be determined with CLSM (Lamprecht et al., 2000a). The location of Nile red 
nanoparticles in macrophages was investigated using CLSM. The staining of the nanoparticles 
and macrophages was performed as described by Wachsmann and Lamprecht (Wachsmann and 
Lamprecht, 2012). Briefly, 200000 macrophages were seeded and incubated for 24 h in a 24-well 
plate containing cover slips. After the removal of the medium 500 µl of Nile red nanoparticles 
(0.1 mg*ml-1) were then incubated with the cells for 2 h at 37 °C. After washing with 500 µl PBS 
twice, the cells were kept at 4 °C for 30 minutes. Afterwards, the PBS was removed the cells 
were incubated with 500 µl concanavalin A (0.1 mg*ml-1) for 5 min. at 4 °C to stain the cell 
membrane. After washing with PBS twice, cells were fixed with 200 µl formaldehyde solution 
(4%) for 10 min. at room temperature. After washing with PBS twice the cells were incubated 
with 200 µl 4',6-diamidino-2-phenylindole (DAPI, 300 nM) for 5 min. to stain the cell nuclei. 
The cells were washed with PBS and after removal of the PBS the cover slips were put on a 
microscope slide to further examine the cells via CLSM. A Nikon Eclipse Ti A1 (Nikon 
Corporation Inc., Tokyo, Japan) was used to investigate the location of Nile red nanoparticles in 
the macrophages. The examination was performed using various magnifications. In order to see 
all three fluorescent labeled compounds (nanoparticles, cell membrane, cell nuclei) the excitation 
wavelength of the laser was set on 405 nm, 488 nm and 543 nm. The fluorescence signals were 
collected using a filter of 450/525/640 nm. To avoid elevated signals a control sample without 
Nile red nanoparticles was examined. 
 
3.5.9 Calculation of surface area of nanoparticles 
The surface area was calculated as explained in the following. The mass of a single particle was 
determined by multiplication of the volume of the particle and the density. A density of 1.2 g/cm3 
was used (Cu and Saltzman, 2008). The amount of particles was then calculated by dividing 1 g 
by the mass of one particle. The number of particles was then multiplied with the surface area of 
a single particle to obtain the surface area of 1 g w/o/w-NP. 
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3.6 Cell culture  
To investigate the different o/w-NP formulations in regard to toxicity and cell uptake, cell culture 
experiments were used. Cell culture experiments cannot simulate the complexity of an immune 
system of an animal, but it does allow for a comparison among the different formulations 
(Nicolete et al., 2011; Treuel et al., 2013). Here, the toxicity, the cell uptake and the location of 
the o/w-NP in the cells were determined. The resuscitation, sub cultivation and cryopreservation 
of the RAW 264.7 cell-line was conducted as previously described (Schmitz, 2011). 
 
3.6.1 Macrophages 
The cell culture experiments were performed with a macrophage cell line (RAW 267.4). The 
cells were kindly provided by the pharmaceutical institute of Besancon (Pharmaceutical 
Technology and Biopharmaceutics). The cell line has been established from murine tumors 
induced with Abelson leukemia virus (Raschke et al., 1978). This mouse-derived cell line 
(BALB/c) exhibits adherent growth (ATCC, 2014). 
A hemocytometer (Neubauer Chamber) was used to count the cells. The hemocytometer is a 
glass slide with a rectangular indentation in the middle that creates a chamber. First, the cover 
slip was properly positioned on the surface of the hemacytometer. 200 µl of the cell suspension 
was then added to the chamber, due to capillary effects the chamber gets completely filled with 
the cell suspension. The number of cells was then counted using a microscope (Motic AE21, 
Wetzlar, Germany). The cells on the 4 large squares, with each square consisting of small 20 
squares, were counted (Fig. 9). The volume of one large square is 0.1 mm3. The concentration of 
the cells was calculated as follows: 
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Eq. 2: A = mean of counted cells in 4 large squares 
   V = volume in which cell pellet was resuspended 
 
 
 
Fig. 9: Hemacytometer grid (left) and counting method (right) 
 
 
3.6.2 Cell culture experiments 
The toxic effects of the o/w-NP on macrophages were tested using a MTT-assay. The cell uptake 
and the location of the o/w-NP were investigated using Nile red nanoparticles. Here, Nile red was 
added during the preparation of the o/w-NP. 1 mg of Nile red was dissolved in 1 ml ethyl acetate. 
100 µl of this solution was added to the organic phase during the preparation of the o/w-NP 
which resulted in a final concentration of 10 µg/ml Nile red in the nanoparticle formulation. 
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3.6.2.1 MTT assay 
The MTT-assay was used to determine the toxicity of nanoparticles on macrophages. It is based 
on the principle that 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) is 
reduced to its corresponding insoluble purple colored formazan in living cells (Mosmann, 1983). 
It was shown that the cofactors NADH and NADPH play an important role in the reduction of 
MTT (Berridge and Tan, 1993). The MTT reduction does not only occur in mitochondria, but 
also the cytoplasm and membranes including endosome, lysosome and the plasma membrane 
(Berridge et al., 2005). The assay was used to investigate the toxicity of the different o/w-NP 
formulations and to determine the concentration in which the o/w-NP formulation can be used for 
further studies without harming the cells. 100000 cells/well were seeded in a 96-well plate and 
incubated for 24 h at 37 °C and 5% CO2 in an incubator. After 24 h the medium was removed 
and 200 µl of different concentrations (3 mg/ml; 1 mg/ml; 0.3 mg/ml; 0.1 mg/ml; 0.03 mg/ml) of 
the o/w-NP were added into the wells. PBS was used as a control. After 8 h of incubation at 37 
°C and 5% CO2 the wells were washed two times with PBS. Then 20 µl of MTT (5 mg/ml) and 
180 µl of medium were added and again incubated for 2 hours. Then the medium was carefully 
withdrawn without syphoning off any formazan crystals. A mixture of DMSO, acetic acid and 
SDS (99.4 ml/0.6 ml/10 g) was then added to dissolve the formazan crystals. The amount of 
formazan was determined photometrically at 570 nm using a plate reader (1420 Multilabel 
Counter Victor3 V, PerkinElmer, USA).  
 
3.6.2.2 Uptake of Nile red nanoparticles into macrophages 
Nanocarriers can be internalized by mammalian cells via different pathways, e.g. phagocytosis, 
clathrin-mediated endocytosis, caveolae-mediated endocytosis, macropinocytosis or other 
clathrin- and cavoelae- independent endocytosis (Hillaireau and Couvreur, 2009). It was already 
reported, that the internalization can be dependent on size (Gaumet et al., 2009) and surface 
properties (Foged et al., 2005; Wachsmann et al., 2013). In the present work, we determined the 
quantitative cell interaction between macrophages and Nile red nanoparticles. 100000 cells/well 
were seeded in a 96-well plate and incubated for 24 h at 37 °C and 5% CO2 in an incubator. After 
24 h the medium was removed and 200 µl of the Nile red nanoparticle formulations (0.1 mg/ml) 
Materials and Methods 
 
42 
 
was added to the wells. The plates were then incubated for various amounts of time (0.5 h; 1 h; 2 
h; 4 h; 6 h; 8 h). PBS was used as a control. When the incubation was done, the supernatant was 
removed and the wells were washed with PBS to get rid of any nanoparticles that were not 
internalized. The fluorescent dye was then extracted by adding 200 µl of ethanol. The 96-well 
plate was agitated and the fluorescence was measured using a plate reader (1420 Multilabel 
Counter Victor3 V, PerkinElmer, USA) at 544 nm/615 nm. 
 
3.7 In vivo experiments 
The immune response of the o/w-NP and the LPS-NP was determined by animal experiments 
using BALB/c mice. As a model protein OVA was used. This is a well-established in-vivo model 
to simulate adjuvant effects (Demento et al., 2009; Gutierro et al., 2002b; Kasturi et al., 2011). 
 
3.7.1 BALB/c mouse 
The BALB/c mice were purchased from Charles River (Sulzfeld, Germany). The BALB/c mouse 
is an albino and laboratory bred strain. All experiments were carried out in the “Haus für 
Experimentelle Therapie” (HET) in Bonn. The mice were 4 weeks old and weighed 25-35 g. 
Only male mice were used. The animal trial began after an acclimation period of seven days. The 
mice were fed with autoclaved standard food (ssniff, Soest, Germany) and water ad libitum. 3-5 
mice were kept in one cage and the cages were changed once a week. Individually Ventilated 
Cages (IVCs) were used in this study. The cages were kept in a room with a temperature of 22 °C 
and an overpressure of 150 Pa. The relative humidity was approximately 50-60%.  
 
3.7.2 Study outline 
The influence of OVA loaded carriers was investigated using a mouse-model. Therefore, five in-
vivo studies were conducted. The immune response of nanoparticles and different adjuvant 
formulation was tested. PLGA particles have already shown that they can have an effect on the 
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immune response (Gutierro et al., 2002a; Waeckerle-Men and Groettrup, 2005). In the presented 
work, we investigated different adjuvant formulations (in-vivo study III) and the effect of 
different o/w-NP formulations (in-vivo study I-II and IV-V). For all in-vivo trials the animals 
were immunized two times and blood samples were drawn three (in vivo study III-V) or four 
times (in vivo study I-II) (Fig. 10).  
 
 
Fig. 10: Study outline of in vivo studies with BALB/c mice 
 
All animal experiments started with marking the mice. Therefore, an ear puncher that was kindly 
provided by the HET was used. Depending on the number of mice in one cage, either 4 mice or 2 
mice were marked. 
The immunization was performed subcutaneously in the neck using a 23 G needle (B. Braun, 
Melsungen, Germany) on study day (SD) 0 and on SD 21. The OVA solution or nanoparticle 
formulation was drawn up in the syringe and 100 µl was injected in each mouse. The needle was 
always changed for each mouse. The blood withdrawal from the tail was done using a 22 G 
needle (B. Braun, Melsingen, Germany) and micro haematocrit tubes (Brand, Wertheim, 
Germany). Approximately 50-100 µl blood was drawn and put in an Eppendorf cup, while the 
mouse was fixed in a restrainer. The blood was stored at room temperature for approximately one 
hour. Then it was stored at 4 °C for 24 hours. Afterwards, it was centrifuged at 19000 rcf for 15 
min. using a Hermle Z 233 M-2 (Hermle Labortechnik, Wehingen, Germany). Then 
approximately 10-20 µl of the blood serum (supernatant) was collected and stored at -20 °C.  
The injection site of the animals was monitored daily after the subcutaneous injection for three 
days and then once a week. Several abort criteria were set to guarantee minimal distress for the 
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animals (GV-SOLAS, 2009). If any of the following signs were observed, the experiment with 
this animal was terminated by euthanizing: 
a) abnormal body posture 
b)  loss of mobility 
c) visible inflammations 
d) weight loss ≥ 20% 
 
3.7.2.1 Carbopol and ovalbumin loaded nanoparticles in mice 
In the first two in-vivo studies the immune response of OVA loaded PVA (1%)-NP and OVA 
loaded Tween (1%)-NP was investigated (Table 7 and  
Table 8). Six groups containing 4-5 mice were tested. Carbopol was used as an adjuvant (0.1% 
w/v) and the OVA concentration was 10 µg per dose in all groups. To see the effect of the 
adjuvant Carbopol, three groups were immunized with addition of Carbopol and three groups had 
no Carbopol. PBS with Carbopol and PBS without Carbopol were used as a control to see the 
effect of the PVA-NP and the Tween-NP. The blood samples were taken on SD 0, SD 21, SD 35 
and SD 42. 
 
Table 7: Experimental groups – in vivo study I 
Group Formulation Ovalbumin Adjuvant Number of mice 
 
I Tween 20 (1%)-NP 10 µg 100 µg Carbopol 5 
II Tween 20 (1%)-NP 10 µg - 4 
III PVA (1%)-NP 10 µg 100 µg Carbopol 5 
IV PVA (1%)-NP 10 µg - 4 
V PBS 10 µg 100 µg Carbopol 4 
VI PBS 10 µg - 4 
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Table 8: Experimental groups – in vivo study II 
Group Formulation Ovalbumin Adjuvant Number of mice 
 
I Tween 20 (1%)-NP 10 µg 100 µg Carbopol 5 
II Tween 20 (1%)-NP 10 µg - 5 
III PVA (1%)-NP 10 µg 100 µg Carbopol 5 
IV PVA (1%)-NP 10 µg - 5 
V PBS 10 µg 100 µg Carbopol 5 
VI PBS 10 µg - 5 
 
 
3.7.2.2 In vivo testing of different Adjuvants 
In the third animal experiment (Table 9) different adjuvant formulations were tested in regard to 
the immune response. The OVA concentration was 10 µg per dose in all groups. PBS with OVA 
acted as a control group. The second group contained OVA and CFA for the first immunization 
and IFA for the second immunization. The adjuvant protein emulsion was formed as described 
above (3.1.9). This group acted as a positive control, since the intense immune response in mice 
after the administration of CFA is widely known (Aucouturier et al., 2001; Schnare et al., 2001; 
Singh and O'Hagan, 2003). The third group and fourth group were the experimental groups. Here 
we compared the immune response of LPS-NP combined with CpG with soluble LPS combined 
with CpG. Since CFA and IFA are highly toxic and dangerous, the mice in this group were 
anesthetized with isofluran (Forene®, Abbott, Germany) during the immunization. The blood 
withdrawal took place on SD 0, SD 21 and SD 35. 
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Table 9: Experimental groups – in vivo study III 
Group Formulation Ovalbumin Adjuvant Number of mice 
 
I PBS 10 µg - 5 
II PBS 10 µg CFA/IFA (50%) 6 
III LPS (1 µg)-NP 10 µg 5 µg CpG 6 
IV PBS 10 µg 5 µg CpG; 1 µg LPS 5 
 
 
3.7.2.3 Lipopolysaccharide loaded nanoparticles and ovalbumin loaded 
nanoparticles in mice 
In the fourth in-vivo study (Table 10) the effect of five different o/w-NP formulations on the 
immune response was tested. The OVA concentration was 10 µg per dose in all groups and LPS-
NP (LPS concentration 1 µg per dose) coupled with CpG (5 µg per dose) was used as an adjuvant 
in all groups. The first group was the control group, containing free OVA and the adjuvant 
formulation. The eighth group was also a control group, containing free OVA without the 
adjuvant formulation. The other groups were the experimental groups. OVA was loaded on 
nanoparticles as described above (see 3.2.1). The resulting nanoparticle formulations were tested. 
Group II contained the Tween 20 (1%)-NP, Group III the PVA (1%)-NP, Group IV the Sodium 
cholate (0.05%)-NP, Group V the SDS (0.01%)-NP and Group VI the CTAB (0,05%)-NP. The 
blood withdrawal was on SD 0, SD 21 and SD 35. 
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Table 10: Experimental groups – in vivo study IV 
Group Formulation Ovalbumin Adjuvant Number of mice 
 
I LPS-NP 10 µg LPS (1 µg)-NP; 5 µg CpG 6 
II Tween 20 (1%)-NP 10 µg LPS (1 µg)-NP; 5 µg CpG 6 
III PVA (1%)-NP 10 µg LPS (1 µg)-NP; 5 µg CpG 6 
IV Sodium cholate 
(0.05%)-NP 
10 µg LPS (1 µg)-NP; 5 µg CpG 6 
 
V SDS (0,01%)-NP 10 µg LPS (1 µg)-NP; 5 µg CpG 5 
VI CTAB (0,05%)-NP 10 µg LPS (1 µg)-NP; 5 µg CpG 6 
VII PBS 10 µg - 6 
 
 
3.7.2.4 Influence of nanoparticle concentration on immune response in mice 
In the fifth in-vivo study (Table 11) the effects of the nanoparticle concentration on the immune 
response was investigated. An OVA solution in PBS coupled with LPS-NP (LPS concentration 1 
µg per dose) and CpG (5 µg per dose) was used as an adjuvant in all groups, including the control 
group. The nine experimental groups had all the same amount of OVA in their formulation (10 
µg per dose). CTAB (0,05%)-NP, Tween 20 (1%)-NP and PVA (1%)-NP were tested in different 
concentrations. The particles were prepared as described before (see 3.2.1) with slight deviations. 
Briefly, the PLGA amount was changed (100 mg/ml and 4 mg/ml instead of 20 mg/ml) and the 
sonication duration was adjusted, in order to obtain comparable nanoparticle sizes. The blood 
withdrawal was performed on SD 0, SD 21 and SD 35. 
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Table 11: Experimental groups – in vivo study V 
Group Formulation PLGA 
concentration 
[mg/ml] 
Adjuvant Number 
of mice 
 
I LPS-NP - LPS (1 µg)-NP; 5 µg CpG 5 
II CTAB (0,05%)-NP 2 LPS (1 µg)-NP; 5 µg CpG 5 
III Tween 20 (1%)-NP 2 LPS (1 µg)-NP; 5 µg CpG 5 
IV PVA (1%)-NP 2 LPS (1 µg)-NP; 5 µg CpG 5 
V CTAB (0,05%)-NP 10 LPS (1 µg)-NP; 5 µg CpG 5 
VI Tween 20 (1%)-NP 10 LPS (1 µg)-NP; 5 µg CpG 5 
VII PVA (1%)-NP 10 LPS (1 µg)-NP; 5 µg CpG 5 
VIII CTAB (0,05%)-NP 50 LPS (1 µg)-NP; 5 µg CpG 4 
IX Tween 20 (1%)-NP 50 LPS (1 µg)-NP; 5 µg CpG 5 
X PVA (1%)-NP 50 LPS (1 µg)-NP; 5 µg CpG 5 
 
 
3.7.2.5 IgG-ELISA 
The blood samples of the in-vivo studies were left to thaw overnight in a fridge (-20 °C) and then 
measured using the Mouse Anti-Ovalbumin IgG kit from Alpha Diagnostics (San Antonio, 
USA). The ELISA (Fig. 11) was carried out as described in the manual (Instruction Manual No. 
M-600-105-OGG). Briefly, after preparing a “washing solution” as well as a solution to dilute the 
samples, the 96-well plate that was covered with OVA was washed using the “washing solution”. 
Meanwhile, all samples were appropriately diluted (100-500000x). 100 µl of standards and 
samples were added to the plate and incubated for 60 min. to bind the IgG on the immobilized 
OVA on the wells. After several washing steps, 100 µl of an IgG-specific antibody conjugated 
with horseradish peroxidase (HRP) was added and incubated for 30 minutes. The IgG-specific 
antibody was bound to IgG. After several washing steps the excess of the free IgG- specific 
antibody conjugated with HRP was washed off. Then 100 µl of 3,3’,5,5’-Tetramethylbenzidine 
(TMB) was added as a chromogenic substrate. The HRP reacted with the TMB to a blue colored 
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product. TMB was oxidized by HRP, resulting in a diimine (Veitch, 2004). By adding 100 µl 
sulfuric acid (1%) the TMB turned yellow. The absorbance was then measured at 450 nm using a 
plate reader (1420 Multilabel Counter Victor3 V, PerkinElmer, USA). The amount of mouse IgG 
in the samples was calculated relative to anti-ovalbumin reference calibrators. The results were 
indicated as IgG Antibody Activity Units (U*ml-1).  
 
 
 
Fig. 11: Principle of mouse anti-OVA IgG-ELISA 
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3.8 Statistical analysis  
The statistical analysis was carried out using Sigmastat 2.0 Software. Statistical difference was 
investigated by Kruskal-Wallis Anova on Ranks followed by multiple comparisons with Student 
Newman-Keuls test. The data was expressed as mean ± SD, p < 0.05 was considered to be 
significant. 
 
Results and Discussion 
 
51 
 
4 Results and Discussion 
 
4.1 Nanoparticles prepared with the double-emulsion-solvent-evaporation 
method 
The encapsulation of hydrophilic drugs, such as proteins and peptides, into nanoparticles is 
challenging. The double-emulsion method is the gold-standard for this process (Bilati et al., 
2005). However, there is still a lack of understanding concerning the morphology of 
nanoparticles, as imaging techniques used to determine the morphology only provide pictures 
showcasing the external structure. Mostly SEM (Gutierro et al., 2002b) or transmission electron 
microscopy (Khoee and Yaghoobian, 2009) were used to investigate the morphology. Basically, 
most analyses concerning the morphology came to the conclusion that spherical nanoparticles 
were obtained (Zambaux et al., 1998), conclusions about the interior morphology could not be 
drawn. Nevertheless, the current understanding is that the hydrophilic drug is encapsulated inside 
the nanoparticles when utilizing the double-emulsion method (Lamprecht et al., 2000b). This 
postulated structure does not comply with the findings made in this thesis. As explained in the 
following, the understanding regarding the structure of nanoparticles prepared by the double-
emulsion method needs to be revisited. 
 
4.1.1 Physicochemical characterization of nanoparticle properties  
4.1.1.1 Influence of surfactant and organic solvent on particle size and 
polydispersity 
Particles were prepared using various amounts of PVA in the outer water phase and BSA in the 
inner phase. In agreement with previous studies (Lamprecht et al., 2000b; Zambaux et al., 1998) 
nanoparticles could be obtained, using a double-emulsion evaporation method. Actually, also 
microparticles were obtained, when using less than 0.1% PVA in the outer water phase (Fig. 12). 
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The aim was to get nanoparticle formulations of different particle sizes for the studies regarding 
the interior morphology. A first approach was simply changing the concentration of PVA in the 
outer water phase, without varying any other parameter, e.g emulsification duration or PLGA 
concentration, in the production of the nanoparticles. 
 
 
Fig. 12: Particle size of w/o/w-NP prepared with methylene chloride or ethyl acetate at various 
PVA concentrations (mean diameter ± SD, n = 3) 
 
A higher amount of PVA has two effects: Firstly, the primary emulsion is better stabilized, due to 
more PVA that can stabilize the interface. Secondly, the viscosity of the outer water phase 
increases, thereby mechanically preventing the formed droplets from merging again. This leads to 
smaller particles, with increasing concentrations of PVA. However, nanoparticles could only be 
obtained at a PVA concentration above 0.1%. The viscosity of the continuous phase is too low 
and PVA does not have sufficient surfactant activity otherwise. 
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In regard to the mean diameter of the particles, methylene chloride and ethyl acetate showed 
similar results. Only at 3% PVA a significant difference could be observed. 
The goal was to prepare nanoparticle formulations with different particle sizes to compare them 
with regard to their release profile and morphology. Instead of changing a lot of parameters, only 
the amount of PVA was altered to keep the set up as simple as possible.  
Depending on the application, w/o/w-NP are prepared in different size ranges. If an uptake into 
cells is desired, smaller nanoparticles, with a mean diameter of around 200 nm showed to have an 
advantage over bigger particles in the sub-micron to microparticle range (Foged et al., 2005). 
Nanoparticles prepared by the double emulsion method that showed promising results in-vivo 
regarding the enhancement of an immune response were in a size range of 250 nm – 400 nm 
(Kasturi et al., 2011). Therefore, this size range is of particular interest, as an in-vivo success has 
already been reported; however, the structural morphology of the nanoparticles applied in that 
study was apparently not investigated. Methylene chloride was mainly used as an organic solvent 
in most studies (Kasturi et al., 2011; Lamprecht et al., 2000b; Zambaux et al., 1998), which is 
why further characterization of the w/o/w-NP was performed with particles prepared using 
methylene chloride. Using 0.5% PVA, nanoparticles with a mean diameter of 332 nm ± 35 nm 
were obtained, which lies in the desired particle size range mentioned above. Furthermore, bigger 
particles of 648 nm ± 80 nm were obtained, using 0.1% PVA. To determine if the particle size 
has an influence on the morphology and release kinetics, these w/o/w-NP types were also further 
characterized in that respect.  
The polydispersity index is dimensionless and provides information about the size distribution. A 
value close to 0.005 indicates that the investigated particle collective has a monomodal size 
distribution. Higher values of above 0.05-0.1 indicate that the particle collective exhibits a 
bimodal size distribution. In the case of the w/o/w-NP that were prepared a low polydispersity 
index was seen for formulations that were prepared using PVA concentration up to 0.5% (Fig. 
13). Higher PVA concentrations led to smaller nanoparticles that are reported to generally have 
bigger polydispersity indices (Zambaux et al., 1998). To lower the polydispersity index for 
smaller nanoparticles the double-emulsion would require stabilization with additional surfactants. 
Our goal was to characterize the w/o/w-NP that are usually obtained, when applying the double-
emulsion method. Therefore, attempts to obtain a monomodal size distribution for nanoparticles 
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that were prepared with 1% PVA or even higher amounts of PVA were not made. Besides, when 
using 0.5% PVA, nanoparticles of around 300 nm were obtained. These nanoparticles have a 
monomodal size distribution and are sufficient for further characterization, making the w/o/w-NP 
with high PVA concentrations and a high polydispersity expendable for the investigation of the 
interior morphology of the nanoparticles.  
 
 
Fig. 13: Polydispersity Index of w/o/w-NP prepared with methylene chloride or ethyl acetate at 
increasing PVA concentrations (mean ± SD, n = 3) 
 
 
4.1.1.2 Loading rate of nanoparticles 
The encapsulation efficiency of the nanoparticles was determined by an indirect method as the 
supernatant of a centrifuged w/o/w-NP sample was measured regarding its BSA content. The 
amount of BSA encapsulated increased with higher PVA concentrations (Fig. 14). This is due to 
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the fact that PVA stabilizes the double-emulsion. Apparently, higher PVA concentrations 
stabilize the double-emulsion better, and leaking of the protein to the continuous phase, which is 
the major cause for low encapsulation efficiency when preparing w/o/w NPs, can be minimized 
(Bilati et al., 2005). 
Another reason for high loading rates with higher PVA concentrations is the fact, that smaller 
w/o/w-NP, which were obtained with increasing amount of PVA, have a larger surface area. 
Thereby, more protein that is present in the continuous phase is able to adsorb to the surface of 
the nanoparticles.  
 
 
Fig. 14: Loading rate of w/o/w-NP loaded with BSA (1 mg/ml) at various PVA concentrations 
using methylene chloride or ethyl acetate as the organic solvent for the polymer (mean ± SD; 
n = 3) 
 
Nanoparticles prepared with methylene chloride as an organic solvent showed a steady increase 
of the loading rate with decreasing particle sizes (Fig. 15). For particles with a mean diameter of 
Results and Discussion 
 
56 
 
648 nm ± 80 nm to 1.29 µm ± 0.13 µm the encapsulation efficiency is between 37% ± 6% to 53% 
± 4%. An increase of the encapsulation efficiency can be seen when using nanoparticles with a 
mean diameter of less than 332 nm. The encapsulation efficiency is more than 90%, which can be 
attributed to the large surface area existing in such small particles. The data indicate that the 
particle size is the deciding factor in regard to the particle size.  
 
 
Fig. 15: Loading rate of w/o/w-NP loaded with BSA (100 µg/mg PLGA-NP; mean ± SD; n = 3)) 
for different particle sizes (mean diameter ± SD; n = 3) using methylene chloride as the organic 
solvent for the polymer 
 
The surface area of the w/o/w-NP decreased with increasing PVA concentrations (Table 12). The 
surface area is logarithmically proportional to the particle size. A larger surface area on the 
nanoparticles enables more protein to adsorb at the surface (Fig. 14). Hence, higher loading rates 
for particles with a larger surface area, lead to the assumption that adsorption of the protein on 
the surface occurs.  
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Table 12: Surface area of w/o/w-NP prepared by double-emulsion method with either methylene 
chloride or ethyl acetate as an organic solvent 
PVA  Surface area of 1 g w/o/w-NP [nm2] 
[g/100 ml] Methylene chloride Ethyl acetate 
0.01 3.87 × 1018  
0.03 4.63 × 1018  
0.1 7.72 × 1018 8.14 × 1018 
0.5 1.51 × 1019 1.49 × 1019 
1 1.72 × 1019 1.88 × 1019 
3 1.86 × 1019 6.26 × 1019 
 
 
Using ethyl acetate as an organic solvent is reported to be challenging when targeting high 
encapsulation rates, as it is partly miscible with water. Because of that, parts of the inner phase 
may leak into the continuous phase more easily compared to the usage of methylene chloride as 
an organic solvent. Consequently, lower encapsulation rates are typically achieved when using 
ethyl acetate as an organic solvent for the double-emulsion method (Bilati et al., 2005). 
Interestingly, encapsulation rates were similar when using ethyl acetate and methylene chloride in 
this work. Only when using high amounts of PVA (more than 1%), the encapsulation was 
different, and nanoparticles prepared with ethyl acetate showed a lower encapsulation rate. This 
can be attributed to the properties of the ethyl acetate mentioned above. 
 
4.1.1.3 Release test of protein loaded nanoparticles 
It had been suggested previously that the hydrophilic drug is encapsulated inside of the polymeric 
matrix (Lamprecht et al., 2000b). The release profile of the tested w/o/w-NP formulations in PBS 
gave surprising insights. Almost every w/o/w-NP formulation showed an immediate release of 
BSA within 1 hour (Fig. 16). These findings are in strong contrast to the postulated structure of 
the nanoparticles prepared by the double-emulsion method (Bilati et al., 2005; Blanco and 
Alonso, 1997; Zambaux et al., 1998). 
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Fig. 16: In-vitro BSA release of w/o/w-NP prepared with different PVA concentrations in the 
outer water phase. + indicates that BSA was added to the outer water phase, instead of the inner 
water phase (mean ± SD; n = 3) 
 
However, a fast release like it was observed in the presented experiments cannot be attributed to 
polymer degradation, as it takes several weeks for PLGA to degrade under these conditions 
(Mäder et al., 1998). 
An immediate diffusion of the active ingredient through the polymer matrix would also take more 
time than monitored (Mäder and Weidenauer, 2010). Hence, it is much more likely that BSA is 
simply adsorbed to the surface and not dispersed within the polymeric matrix. Only for w/o/w-
NP at a size range of above 650 nm a slower release of BSA was seen. Here, about 40% was 
immediately released, whereas after 24 h 70% of BSA was released. This suggests that about 
40% of the BSA was located at the surface of the nanoparticles and that 60% were in fact 
encapsulated inside.  
To confirm this hypothesis, w/o/w-NP were prepared with the alteration that BSA was added to 
the continuous phase (w2) instead of the inner water phase (w1). These nanoparticles had the 
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protein definitely adsorbed to the surface, because the inner water phase did not contain BSA. 
Therefore, nanoparticles were obtained that possessed a distinct structure. The obtained 
nanoparticles showed release profiles that were very similar to those of the particles in which 
BSA was present in the inner w1–phase (Fig. 16).  
A difference was visible for particles with a mean particle size larger than 650 nm. As mentioned 
above the w/o/w-NP with the BSA in the inner phase did not show a complete release of the BSA 
within 24 hours. Particles in a similar size range with BSA present in the continuous phase, but 
not the inner phase, did show an immediate release of the hydrophilic drug. The difference can be 
contributed to the fact that, for particles above a certain size, a part of the BSA is really 
encapsulated inside the particles.  
A fast release within 4 hours has been previously reported for PLGA nanoparticles, prepared by 
the double-emulsion method, containing alendronate (Cohen-Sela et al., 2009). However, our 
findings differ from previous studies, in which proteins or glycosaminoglycans have been used as 
the API, with regard to the observed release profiles (Jiao et al., 2002; Lamprecht et al., 1999; 
Sahana et al., 2010). This can partly be attributed to conditions during the drug release test. There 
is no standardized method to measure the release profile of nanoparticles, consequently results 
cannot be sufficiently compared. 
 
4.1.1.4 Morphology of nanoparticles 
 
The release profile of the w/o/w-NP is contradictory to the common understanding of 
nanoparticles with encapsulated API, because the immediate release of BSA would not occur if it 
was in fact encapsulated inside a polymeric matrix. There also seems to be a size dependent 
effect, as particles larger than 650 nm did not show a complete release after 24 h, indicating that 
BSA is partly encapsulated inside the nanoparticles.  
To determine the characteristic of the w/o/w-NP further, the morphology was investigated. The 
interior morphology is of particular interest, as it might explain the findings of the release profile 
that do not fit with current perception of the structural characteristics.  
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Until now, the interior morphology of w/o/w-NP remained undiscovered as imaging techniques 
like transmission electron microscopy (He et al., 2004; Khoee and Yaghoobian, 2009), SEM 
(Giovino et al., 2012), FE-SEM (Sahana et al., 2010) and atomic force microscopy (Lamprecht et 
al., 2000b) were able to confirm the size and determine the shape of w/o/w-NP, but failed to give 
information about the interior morphology and consequently the localization of the hydrophilic 
drug.  
First, w/o/w-NP were investigated using an SEM (Fig. 17). As anticipated, nanoparticles showed 
a spherical shape and the particle size, measured by PCS earlier, could be confirmed. These 
findings were already described multiple times in previous studies as mentioned above.   
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Fig. 17: SEM images of w/o/w-NP prepared with 0.1% PVA at 15 - 17 kV with magnifications of 
250 - 20000 x  
 
Further investigations regarding the morphology were conducted using an FE-SEM. As the 
resolution is much better it is more suitable as imaging technique for nanoparticles compared to 
SEM. 
To obtain satisfactory results about the interior morphology of w/o/w-NP the preparation was 
modified. Instead of BSA a mixture of BSA and Gold-BSA was used. The Gold-BSA is visible 
under the FE-SEM as bright spots.  
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To get a comprehensive insight of the interior morphology of w/o/w-NP different formulations 
were tested. Particles in a size range of about 600 nm prepared with 0.1% PVA and w/o/w-NP in 
a size range of about 300 nm prepared with 0.5% PVA were investigated. 
Gold-BSA is visible on the surface of w/o/w-NP in a size range of 600 nm, proving that at least 
not the entire drug is encapsulated (Fig. 18). 
 
 
Fig. 18: FE-SEM images of w/o/w-NP prepared with 0.1% PVA at 0.1 – 1 kV with magnifications 
of 3500 – 35000 x 
 
The pictures reveal “polymeric bridges” between the w/o/w-NP. These are most likely 
measurement artefacts derived from the drying of the w/o/w-NP. The situation in suspension 
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must be different; otherwise the measured particle size would be substantially bigger. Moreover, 
if the particles were aggregated they would not be homogenously dispersed. 
Another aspect of interest is the surface of the w/o/w-NP, which seems to be either smooth or 
furrowed (Fig. 18). These are also most likely measurement artefacts as the surface is smooth at 
low magnifications and furrowed at high magnifications. The polymeric shell appears to be 
affected by the electron beam leading to damages of the specimen. During the examination of the 
nanoparticles, a change of the surface was discovered when the electron beam remained 
stationary on one area of the sample for a prolonged period. The surface was smooth in the 
beginning, but then a formation of wrinkles could be noted.  
Even though the particle size analysis showed a monomodal size distribution, some microscale 
particles were visible in the FE-SEM pictures. Nevertheless, counting the particles displayed that 
only less than 2% of the total number of particles were bigger than 2 µm, confirming the results 
of the particle size experiments.  
The discoveries and the consequent understanding about the morphology of w/o/w-NP were 
limited, when using FE-SEM on w/o/w-NP with Gold-BSA. Gold-BSA is clearly visible on the 
surface of the particles leading to the conclusion that at least part of the drug is not encapsulated. 
On the other hand, encapsulation rates are rarely 100%. That is why part of the drug is adsorbed 
at the surface, when proper interactions of the drug and the polymer prevail. As reported 
previously, this is the case for PLGA nanoparticles and BSA (Singh et al., 2004).  
To get an insight into the interior morphology of the w/o/w-NP ion milling coupled FE-SEM was 
used. The sample was cut with an argon beam and investigated using FE-SEM in the same 
manner as the sample that was not subjected to ion milling.  
By applying this sample preparation technique, the interior morphology of w/o/w-NP becomes 
visible (Fig. 19). Surprisingly, only very few particles with an inner hollow attributable to an 
inner aqueous phase could be found. Moreover, particles that contained an inner water phase 
were typically in the microscale and not nanoparticles. In fact, the smallest particle with an inner 
aqueous phase had a size of 658 nm. The mean particle size for particles with an inner phase was 
2.32 µm. This is significantly larger than the mean particle size for particles without an inner 
phase, which was 606 nm  
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Besides, only about 11% of all particles even had an inner aqueous phase. It is clearly visible that 
most Gold-BSA is located on the outside of the nanoparticles. The lack of an inner phase 
prevents the drug from being encapsulated. Therefore, the drug is mainly adsorbed at the surface 
of the w/o/w-NP. 
 
 
Fig. 19: FE-SEM images of w/o/w-NP prepared with 0.1% PVA at 1 kV with magnifications of 
4500 – 30000 x after ion milling with an argon beam 
 
Taking these discoveries into consideration, the encapsulation rates (Fig. 14) can be put in 
context. The amount of BSA loaded on the surface is dependent on the surface area of the w/o/w-
NP. Therefore, a higher loading of the particles with BSA can be observed with smaller particles.  
Results and Discussion 
 
65 
 
The findings of the interior morphology also correspond better with the findings of the 
dissolution test. The previously prevailing understanding of the morphology of w/o/w-NP was 
not suitable to explain the release profile (Fig. 16) sufficiently.  
Based on the FE-SEM images it is consistent that most of the BSA is immediately released and 
only a small fraction remains inside the particles after 24 h. BSA on the surface is desorbed from 
the surface, when the properties of the surrounding media change, as they do when conducting a 
dissolution test. 
To obtain informations about the morphology of smaller w/o/w-NP, particles with a mean 
particle size of 350 nm were prepared with 0.5% PVA were investigated using ion milling 
coupled FE-SEM (Fig. 20). It must be stated that the nanoparticles were not all cut at the exact 
center. Ion milling was applied to the nanoparticle sample on a silicium chip with an argon beam; 
consequently particles were not cut individually, leading to the previously shown images.   
As already showcased for the bigger particles prepared with 0.1% PVA, the w/o/w-NP prepared 
with 0.5% PVA also showed almost no inner aqueous phase at all. Actually, for only about 2% of 
the particles an inner aqueous phase was visible. This is consistent with the results discussed 
above, as smaller particles are apparently not able to have an inner aqueous phase. The smallest 
particle with an aqueous phase had a particle diameter of 603 nm. This is similar to the smallest 
particle with an inner aqueous phase found in the earlier experiment, where the mean particle size 
was substantially bigger. 
These findings reveal that the current understanding of the morphology of w/o/w-NP is not 
appropriate for nanoparticles with a mean diameter of below 600 nm and needs to be revisited. 
The protein is mainly adsorbed at the surface of the nanoparticles and it is not encapsulated inside 
the polymeric matrix.  
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Fig. 20: FE-SEM images of w/o/w-NP prepared with 0.5% PVA at 1 kV with magnifications of 
10000 – 20000 x after ion milling with an argon beam 
 
 
4.1.1.5 Investigation of structural peculiarities of nanoparticles 
A double-emulsion method was used to incorporate the hydrophilic drug inside nanoparticles 
consisting of a polymeric matrix. This postulated structure can now be dismissed as the images of 
the ion milling coupled FE-SEM of w/o/w-NP clearly show that the protein is not located inside 
the nanoparticles, but mostly outside at the surface of the nanoparticles.  
Comparing the loading rates of w/o/w-NP in which the BSA was either added to the inner water 
phase or the outer water phase does only show slight differences between the formulations (Fig. 
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21). The loading rate is a little bit higher for the formulations in which the protein was added to 
the inner water phase. It must be stated that the loading rate was measured indirectly by analyzing 
the supernatant of the nanoparticle formulation after centrifugation. Both formulations showed an 
increased loading rate for decreasing particle sizes. This can be simply explained by the larger 
surface area that is available when using smaller particles. This correlation between particle size 
and encapsulation efficiency was expected for samples where BSA had only been added to the 
continuous phase, but not for samples with BSA in the inner phase, as encapsulation rates for e.g. 
microparticles are usually not expected to be dependent on the size when applying the double-
emulsion method. However, this finding becomes plausible in view of the microscopic results 
reported in chapter 4.1.1.4, showing that for w/o/w-NPs where BSA had been added to the inner 
phase during manufacture, BSA was only detectable on the particle surfaces for particles smaller 
than 603 nm. It is also interesting that regardless of the mean particle size of a w/o/w-NP sample 
the size of the inner aqueous phase is similar, making it much more likely for big particles to 
have an inner aqueous phase (Table 13).  
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Fig. 21: Loading rate of w/o/w-NP with BSA (1 mg/ml) either dissolved in the inner water phase 
(w1) or the outer water phase (w2) (mean ± SD; n = 3) 
 
Table 13: Analysis of FE-SEM images regarding the particle size and interior particle 
morphology 
 w/o/w-NP-
0.1% PVA 
w/o/w-NP-
0.5% PVA 
Number of particles with an inner phase 13 2 
Total number of particles  113 90 
Fraction of particles with inner phase 11.5% 2.2% 
Particle size (mean diameter) of all particles 790 nm 370 nm 
Particle size (mean diameter) of particles with an inner 
phase 
2327 nm 1037 nm 
Particle size (mean diameter) of particles without an inner 
phase 
606 nm 356 nm 
Smallest particle (diameter) with an inner phase 658 nm 603 nm 
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Even though the double-emulsion method is used as a gold-standard to encapsulate hydrophilic 
drugs there are a lot of accompanying challenges with it. The hydrophilic drug, e.g. a protein or 
DNA, has to overcome shear stress from the emulsification process. This can, very likely, lead to 
destabilization or even denaturation of many proteins. Furthermore, the hydrophilic drug may 
have to deal with heat during the emulsification process and it comes in contact with an organic 
solvent at the interface of the primary emulsion. All of these hurdles can lead to inactivation of 
the hydrophilic drug. Therefore, the active ingredient used for the preparation must be robust 
enough to withstand the manufacturing conditions associated with this technique. Hence, results 
of model proteins like BSA cannot be transferred to other proteins like antibodies that have 
different properties in terms of size and overall composition. A scale-up to an industrial scale is 
also challenging, because of the complex preparation method. 
As described earlier, the aim of loading a hydrophilic drug inside nanoparticles (particle size ≤ 
600 nm) cannot be successfully carried out using the previously described double-emulsion 
method applied in this work. It cannot, in fact, be called a double emulsion method, as the 
droplets from which the nanoparticles are formed appear to not being capable of holding droplets 
of an inner phase. 
A simpler and better transferable method would be to prepare polymeric nanoparticles of a 
desired particle size and then letting the hydrophilic drug adsorb onto the surface of the 
nanoparticles. 
 
 
Results and Discussion 
 
70 
 
4.2 Nanoparticles prepared with oil-in-water-emulsification-evaporation 
method 
 
As shown previously, nanoparticles prepared by the double-emulsion method do not encapsulate 
the hydrophilic drug inside at a particle size below 600 nm. The hydrophilic drug is adsorbed at 
the surface. Hence, preparing nanoparticles using a simpler approach is beneficial in terms of 
stability of the hydrophilic drug, since it is exposed to shear stress, heat and to an organic solvent, 
when applying the double-emulsion method.  
Therefore, nanoparticles were prepared using an oil-in-water-emulsification-evaporation method. 
The “blank” PLGA-NP were then incubated with the hydrophilic drug, BSA, OVA or α-toxin.  
 
4.2.1 Physicochemical characterization of nanoparticle properties  
4.2.1.1 Influence of surfactants on particle size and polydispersity 
Five different surfactants were used to prepare the PLGA-NP. The nonionic surfactants PVA and 
Tween 20, the anionic surfactants SDS and sodium cholate and the cationic surfactant CTAB 
were used for the preparation. As the protein was adsorbed after the preparation of the PLGA-NP 
it was anticipated that modified surface properties of the PLGA-NP, as a result of different 
surfactants, would have an effect on the loading rates (Fleischer and Payne, 2012).  
As expected, higher amounts of surfactant led to a smaller particle size of the PLGA-NP (Fig. 
22). The emulsion is stabilized with surfactants during the emulsification process via 
ultrasonication. A higher amount of surfactant can stabilize smaller droplets compared to lower 
amounts of surfactants. This ultimately yields smaller particles.  
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Fig. 22: Influence of surfactant concentration on particle size of o/w-nanoparticles (mean 
diameter ± SD, n=3) 
 
The goal was to obtain nanoparticles in the size range of 100 nm – 200 nm (mean diameter). This 
was possible for all formulations, using sufficient amount of the respective surfactant. For PVA-
NP and Tween 20-NP a surfactant concentration of 1% w/v was used to get nanoparticles below 
200 nm, SDS-NP in the desired particle size range were obtained using 0.01% w/v SDS and for 
the CTAB-NP 0.1% w/v CTAB was necessary. Sodium cholate-NP had a particle size of 154 nm 
± 10 nm, when using 0.05% w/v sodium cholate.  
As another important aspect, the polydispersity of the nanoparticle formulations was investigated. 
As mentioned earlier, a high polydispersity indicates that the particle distribution is not 
monomodal. A polydispersity index above 0.05 – 0.1 suggests a bimodal particle size 
distribution. 
The polydispersity index increases with higher amounts of surfactants and consequently increases 
for smaller particles (Fig. 23). 
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Fig. 23: Influence of surfactant concentration on polydispersity of o/w-nanoparticles (mean ± 
SD, n=3) 
 
Polydispersity values close to 0.005 indicate monomodal particle size distributions. This could 
only be observed for particles above 300 nm. Higher amounts of surfactants were evidently 
sufficient to obtain small particles, but failed to obtain nanoparticles with a monomodal particle 
size distribution at a size range of 100 nm – 200 nm.  
 
4.2.1.2 Zeta potential of nanoparticles 
The surface properties of the PLGA-NP were characterized by measurement of the zeta potential 
as described in 3.5.4. The zeta potential changed for each surfactant and showed values of -7 mV 
- -25 mV for the nonionic and anionic surfactants (Fig. 24). The CTAB-NP had a zeta potential 
of -4 mV to 2 mV. 
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Fig. 24: Influence of surfactant concentration on zeta potential of o/w-nanoparticles (mean ± SD, 
n=2) 
 
4.2.1.3 Loading rate of adsorbed proteins on nanoparticles 
The prepared PLGA-NP were further tested regarding their potential to adsorb protein onto the 
surface, using OVA or BSA as model proteins. All formulations, using PVA, Tween 20, SDS, 
sodium cholate, and CTAB were prepared as described in chapter 3.2.1 and investigated.  
OVA showed a high loading to the surface of the nanoparticles at a size below 200 nm (Fig. 25). 
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Fig. 25: Loading rate of O/W-Nanoparticles (10 mg/ml) with 0.1 mg/ml Ovalbumin (mean 
± SD, n=3) 
 
The amount of OVA adsorbed at the surface of the NP increased for smaller particles, when using 
PVA and Tween 20 as surfactants. However, this was not the case for the SDS- and sodium 
cholate- formulations. Especially for SDS-NP the loading rate decreases to 0%, meaning that no 
protein is adsorbed to the surface at a concentration of 0.1% SDS. Even though the particle size 
of the SDS-NP is smaller when using 0.1% SDS (46 nm ± 2 nm) instead of 0.01% (202 nm ± 
16 nm), the loading rate decreases. This is most likely due to the fact that the SDS is repulsing 
the protein on the surface of the PLGA-NP. At low concentrations of SDS OVA is able to adsorb 
at the surface, but not at high SDS concentrations. A similar, but not as drastic effect, can be seen 
when using sodium cholate as a surfactant. The highest loading of OVA can be observed for 
sodium cholate-NP prepared with 0.05% sodium cholate. Increasing the sodium cholate 
concentration to 0.1% results in a lower loading rate, however the difference is not as substantial 
as for the SDS-NP. Like for all other tested surfactants, the particle size also decreases with 
higher surfactant concentrations, which, in theory, should lead to an increase in loading rate as 
smaller particles provide a larger surface available for adsorption. This means, that surface 
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properties such as zeta potential and hydrophobicity are of high importance as the surface area is 
apparently not itself solely responsible for the protein adsorption.  
For the nonionic surfactants PVA and Tween 20 the loading rate follows the understanding that 
higher loading rates can be observed for smaller particles. Here, increasing surfactant 
concentrations yield smaller particles that have a bigger surface area (Table 14). A high amount 
of surfactant does not hinder OVA adsorbtion at the surface, when using the nonionic surfactants 
PVA and Tween 20. Both appear advantageous compared to the anionic surfactants SDS and 
sodium cholate.  
CTAB was used as a cationic surfactant. Surprisingly, OVA does not adsorb at the surface of 
CTAB-NP. Independent of the size of the CTAB-NP and the amount of CTAB used, a loading of 
the CTAB-NP with OVA could not be obtained.  
 
Table 14: Surface area of o/w-NP prepared with different surfactants at various concentrations 
Surfactant 
concentration 
Surface area of 1 g w/o/w-NP [nm2] 
[g/100 ml] PVA-NP Tween 20-NP SDS-NP Sodium 
cholate-NP 
CTAB-NP 
1 35.5 × 1018 25.2 × 1018    
0.3 15.1 × 1018 10.6 × 1018    
0.1 9.1 × 1018 6.1 × 1018 110 × 1018 53.0 × 1018 62.5 × 1018 
0.05   65.7 × 1018 32.4 × 1018 20.4 × 1018 
0.035     6.25 × 1018 
0.01   24.8 × 1018 9.75 × 1018 5.14 × 1018 
 
Another model protein that was used in this work was BSA. The results regarding the loading 
rate of BSA onto the surface of PLGA-NP are similar to those obtained when using OVA as a 
protein. For the nonionic surfactants PVA and Tween 20 the loading rate increases with a bigger 
surface area. PVA-NP do show a slight decrease of the loading rate for 1%, here the high amount 
of PVA affects the loading with BSA negatively. For Tween 20-NP and sodium cholate-NP a 
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higher loading of BSA was observed for smaller nanoparticles, which have a bigger surface area 
(Fig. 26). 
 
Fig. 26: Loading rate of O/W-Nanoparticles (10 mg/ml) with 0.1 mg/ml BSA (mean ± SD, n=3) 
 
SDS-NP showed a similar behavior when comparing the loading of BSA and OVA. Only at a 
concentration of 0.01% a loading with BSA could be observed. This may also be the effect of 
SDS competing with BSA on the surface of the nanoparticles, making an adsorption of BSA at 
high SDS concentrations impossible.  
A loading with BSA on CTAB-NP could also only be observed at the lowest used CTAB 
concentration. This is an improvement compared to the loading with OVA, where a loading was 
not observed. The low loading rate at 0.01% CTAB combined with the fact that no loading was 
possible at higher CTAB concentrations suggests that CTAB competes with the proteins at the 
surface of the nanoparticles, making a loading with the proteins unlikely. 
When comparing the nanoparticle formulations that produced the highest loading with the 
proteins at different protein concentrations, it can be observed that BSA tends to be more 
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adsorbed at the nanoparticle surface compared to OVA (Fig. 27). However, this was not observed 
for all formulations, but for the majority of nanoparticle formulations. The CTAB-NP were not 
included for the comparison of OVA and BSA as a loading with protein on the CTAB-NP surface 
was not observed. BSA causes a lower surface tension in PBS than OVA (Table 18). Therefore, it 
can be assumed that BSA, compared to OVA, accumulates more on interfaces, which could 
explain why the loading rate of BSA is higher on most o/w-NP formulation. However, the 
surface-active properties of the protein are not the only determining factors for the adsorption of 
the protein onto the nanoparticle surface, hydrophobic and ionic interaction also impact the 
ability of the protein to adsorb at the nanoparticle surface (Hillaireau and Couvreur, 2009; 
Lundqvist et al., 2008). The surfactant used for the preparation of the o/w-NP causes a modified 
nanoparticle surface (Singh et al., 2007). Thereby, the loading rate of each protein onto the 
nanoparticle surface must be tested for each o/w-NP formulation as the surface properties of the 
o/w-NP surface changes with each formulation leading to different intensities of ionic and 
hydrophobic interactions with the protein. 
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Fig. 27: Influence of protein concentration on loading rate on (a) PVA (1%)-
Nanoparticles, (b) Tween 20 (1%)-Nanoparticles, (c) Sodium cholate (0.05%)-Nanoparticles and 
(d) SDS (0.01%)-Nanoparticles (mean ± SD, n=3) 
 
The studies regarding release kinetics, stability, morphology, cell interaction and in-vivo 
experiments were conducted using nanoparticle formulations that had a relatively good loading 
rate combined with a small particle size (Table 15).  
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Table 15: Particle formulations used for futher studies 
Nanoparticle formulation (10 
mg/ml) 
Loading rate (OVA 
0.1 mg/ml) [%] 
Mean diameter [nm] 
PVA (1%) 71 ± 2 141 ± 9 
Tween 20 (1%) 83 ± 2 198 ± 28  
Sodium cholate (0.05%) 96 ± 1 154 ± 10 
SDS (0.01%) 66 ± 2 202 ± 16 
CTAB (0.05%) 0 246 ± 142 
 
 
4.2.1.4 Release profile of protein loaded nanoparticles 
The in-vitro release profile of the o/w-nanoparticle formulations (Table 15) prepared using 
different surfactants showed similar results to the nanoparticles prepared with the double 
emulsion method, using only PVA (Fig. 16). 
The o/w-NP showed an immediate release of OVA in PBS (Fig. 28) within 30 minutes. The 
Protein is just adsorbed at the surface, making a fast release possible. A release of about 100% 
was achieved for all nanoparticle formulations. Therefore, the surface modification with the 
surfactants has no influence on the release profile.  
The results of the release profile are slightly defective as the release of the protein was over 
100%. This can be attributed to the fact that the nanoparticle samples were directly measured 
after sampling. The samples were drawn at a temperature of 37°C, the increased temperature of 
the nanoparticle samples compared to the standards led to an increase in the absorption of the 
detected bicinchoninic acid, which is measured when determining the protein content with a 
BCA-assay. 
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Fig. 28: In-vitro OVA release of o/w-NP in PBS at 37 °C (mean ± SD; n = 3) 
 
 
4.2.1.5 Characterization of α-toxoid loaded nanoparticles  
Recombinant proteins are in high demand in vaccine research as they pose as a safer choice 
compared to live, attenuated vaccines. Challenges regarding the immunogenicity have been 
discussed earlier (2.1). In addition to those challenges, recombinant proteins are rarely of a high 
purity making the formulation development difficult. Residual host cell impurities like proteins 
and DNA can interact with the nanoparticles leading to aggregation.  
In this work, α-toxoid from E. coli and α-toxoid from Clostridium perfringens, which can be used 
as vaccines to protect animals against gas gangrene, was tested regarding its compatibility and 
loading rate with o/w-NP. 
The o/w-NP showed promising properties concerning loading rate, stability and compatibility 
when model proteins like BSA and OVA were used. To test if the o/w-NP are also suitable for 
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the formulation with recombinant proteins, α-toxoid from E. coli was tested. Furthermore, α-
toxoid derived from Clostridium perfringens was also tested.  
The PLGA o/w-NP were loaded with α-toxoid as described in chapter 3.2.1. Before the proteins 
were incubated with the o/w-NP the nanoparticles were freeze dried as previously described 
(3.4). The protein solution was then incubated for 3 h with the freeze dried nanoparticles. PLGA 
nanoparticles were used in a concentration of 12.5 mg/ml in the loading experiment.  
The α-toxoid from E. coli was added to yield a final concentration of 0.065 mg/ml and the α-
toxoid from Clostridium perfringens was added to yield a concentration of 0.0215 mg/ml in the 
nanoparticle formulation.  
The α-toxoid from E. coli was easier to formulate with nanoparticles, except for the CTAB-NP 
all formulations formed stable nanoparticle suspension (Table 16). Visual aggregation after 
blending of nanoparticle formulation and protein was considered as “instable”. 
The α-toxoid from Clostridium perfringens was not stable when blending with the ionic o/w-NP. 
Precipitation was observed during incubation of the α-toxoid from Clostridium perfringens with 
SDS-NP, sodium cholate-NP, and CTAB-NP. The formulation was physically stable when the 
nonionic PVA or Tween 20 was used for the preparation of the o/w-NP.  
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Table 16: Compatibility of different O/W-Nanoparticle formulations with α-toxoid from E. coli 
and α-toxoid from Clostridium perfringens. (+) indicates that blend of nanoparticle formulation 
and protein solution is suitable for further testing. (-) indicates that precipitation occurred during 
blending process (n= 3-4).  
Nanoparticle formulation α-toxoid (E.coli) α-toxoid (Clostridium 
perfringes) 
PVA (1%) + + 
Tween 20 (1%) + + 
Sodium cholate (0.05%) + - 
SDS (0.01%) + - 
CTAB (0.05%) - - 
 
 
The protein is not extensively purified, which is visible in the SDS-PAGE gels (Fig. 29). The α-
toxoid from E. coli has a purity of approximately 50% and the α-toxoid from Clostridium 
perfringens has a purity of approximately 25%. As the proteins are unpurified a BCA-assay 
cannot give reliable results concerning the adsorption of the toxoids on the surface, because the 
total amount of protein is measured when applying a BCA-assay, the method is not specific for α-
toxoid. Therefore, SDS-PAGE was used to measure the amount of the different proteins on the 
surface of the nanoparticles. An indirect method was used, as mentioned previously (3.5.2).  
It must be noted that some o/w-NP formulations were unstable when blending with the toxoids. 
Precipitation was observed for some formulations, this is important when examining the gels, as 
an indirect method was applied measuring the protein in the supernatant of the o/w-NP after 
incubation. In case of precipitation, the toxoid formed agglomerates with the nanoparticles, and 
the supernatant did not contain any toxoid. Consequently, even if no protein was detected in the 
supernatant, which would normally mean that 100% is adsorbed at the nanoparticle surface, 
adsorption of the toxoid to the nanoparticle surface did not take place, if precipitation occurred 
during the incubation. In this context, the supernatant of CTAB-NP, for example, contained no 
toxoid at all (Fig. 29), and this is attributed to the fact that CTAB-NP agglomerated with the 
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protein solutions (Table 16). CTAB-NP were therefore considered not to be suitable for either, α-
toxoid from E. coli or α-toxoid from Clostridium perfringens.  
 
Fig. 29: SDS-PAGE gels after staining with Coomassie Brilliant Blue, supernatants of o/w-NP 
formulations after incubation with toxoids and standard of toxoids; a) α-toxoid (E.coli): 1) 
Marker 2) PVA-NP 3) Tween 20-NP 4) Sodium cholate-NP 5) SDS-NP 6) CTAB-NP 7) α-toxoid 
(E.coli) 0.065 mg/ml 8) α-toxoid (E.coli) 0.049 mg/ml 9) α-toxoid (E.coli) 0.0325 mg/ml 10) α-
toxoid (E.coli) 0.016 mg/ml; b) α-toxoid (Clostridium perfringes): 1) PVA-NP 2) Tween 20-NP 3) 
Sodium cholate-NP 4) SDS-NP 5) CTAB-NP 6) Marker 7) α-toxoid (Clostridium perfringes) 
0.0054 mg/ml 8) α-toxoid (Clostridium perfringes) 0.0108 mg/ml 9) α-toxoid (Clostridium 
perfringes) 0.0161 mg/ml 10) α-toxoid (Clostridium perfringes) 0.0215 mg/ml 
 
The o/w-NP using anionic surfactants for the preparation (SDS and sodium cholate) also 
precipitated when mixing with the α-toxoid from Clostridium perfringens. Hence, these 
formulations are not appropriate for this protein. However, the formulations with α-toxoid from 
E. coli were successful regarding their physical stability. Here, the amount of protein in the 
supernatant could be used to calculate the loading rate of the toxoid to the nanoparticle surface. 
For the o/w-NP using nonionic surfactants (PVA and Tween 20) formulations with both toxoids 
were physically stable, consequently supernatant was used to determine the amount of toxoid on 
the o/w-NP surface. 
The SDS-PAGE gels were visualized with an Intas® camera system and a densiometric analysis 
was performed using the imageJ software. The experiments in which the loading of o/w-NP with 
α-toxoid from E. coli was tested could be easily evaluated, as the proteins from the vaccine 
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formulation were clearly separated and had a high enough concentration to be sufficiently visible 
for a quantitative measurement (Fig. 29a).  
 
The o/w-NP prepared with the nonionic surfactants PVA and Tween 20 showed the highest 
loading with α-toxoid from E. coli with loading rates of 94% ± 6% and 96% ± 1%, respectively 
(Table 17). The sodium cholate-NP also showed a high loading rate of 80% ± 1% and the SDS-
NP had a loading rate of 41% ± 10%. 
 
Table 17: Loading rate of o/w-NP with α-toxoid (E.coli) 
Nanoparticle 
formulation 
α-toxoid (E.coli) 
loading rate [%] 
PVA (1%) 94 ± 6 
Tween 20 (1%) 96 ± 1 
Sodium cholate (0.05%) 80 ± 1 
SDS (0.01%) 41 ± 10 
CTAB (0.05%) - 
 
 
The analysis of the o/w-NP with α-toxoid from Clostridium perfringens was challenging, as the 
bands of the targeted protein were not clearly visible (Fig. 29). Therefore, in addition to testing 
the supernatant of the o/w-NP after incubation with the vaccine formulation, the o/w-NP 
themselves were tested as well. Here, the centrifuged o/w-NP were redispersed with 10% SDS 
and 2.3% DTT. The test does not give a quantitative result for the loading rate of the α-toxoid on 
the o/w-NP, because some agglomerates remained after redispersing the sample. A qualitative 
conclusion could be made nevertheless, as it is clear that at least some part of the α-toxoid from 
Clostridium perfringens was adsorbed at the surface of the o/w-NP (Fig. 61).  
The loading of o/w-NP with the two toxoids could be achieved when using the nonionic 
surfactants PVA and Tween 20 for the preparation of the nanoparticles. Furthermore, the SDS-
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NP and sodium cholate-NP could be used for the α-toxoid from E.coli, but not for α-toxoid from 
Clostridium perfringens. The CTAB-NP are not suitable, as precipitation occurred regardless 
which of the two toxoids were used. Apparently, the cationic nanoparticles interacted with 
compounds in the protein solution. The protein solution was manufactured with E.coli or 
Clostridium perfringens and the purity was under 50%. Recombinant proteins solutions with such 
a poor purity can contain DNA and proteolytic degradation products, which can lead to 
aggregates with ionic substances (Seetharam and Sharma, 1991).  
The characteristics of the α-toxoid from E. coli are similar to those of BSA and OVA regarding 
its size. It has a molecular weight of 43kDa, OVA has a molecular weight of 45 kDa and BSA 66 
kDa. 
The exact mechanism according to which a protein adsorbs to the surface of PLGA nanoparticles 
is not completely identified (Lynch et al., 2007). Hydrophobic interactions of the protein and the 
o/w-NP seem to play a role in the adsorption of the protein to the PLGA surface. A prediction of 
the loading rate for a protein cannot be calculated without experimental testing as the mechanism 
of the adsorption process is not clear. It can be stated that the surfactants that were used to 
prepare the o/w-NP had an effect on the amount of protein that was loaded to the surface. 
Different o/w-NP formulations may lead to different results in regard to the loading rate (Table 
17). The properties of the protein are also important for the loading rate, as different proteins 
result in different loading rates when using the same o/w-NP formulation (Fig. 27). 
 
4.2.1.6 Investigation of possible adsorption mechanisms 
To investigate the protein-nanoparticle interaction several experiments were conducted. The 
loading rate for different proteins at the surface of nanoparticles with different surfactants has 
been described above. Moreover, the surface area was investigated regarding its influence on the 
loading of the proteins. Another aspect, which is crucial for a loading of the proteins on the 
surface of nanoparticles, is the ability of the protein to accumulate on the surface of the 
nanoparticle. This means that the protein must be surface-active. Therefore, the interfactial 
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tension of protein solutions was measured to investigate the influence of the surface tension on 
the loading rate of proteins on the surface of nanoparticles.  
The surface tension of the surfactants and the proteins were tested. As expected the surface 
tension decreases with increasing surfactant and protein concentrations (Table 18 and Table 24). 
Proteins possess the ability to accumulate at interfaces as they have hydrophilic and lipophilic 
properties. In comparison, BSA is more surface-active than OVA. The ability of the model 
proteins to accumulate on interfaces may be one reason, as to why they are adsorbing onto the 
nanoparticles.  
 
Table 18: Surface tension of protein solutions (mean ± SD; n = 3) 
Concentration protein [mg/ml] Surface tension [mN/m] 
 OVA BSA 
0.1 61.8 ± 0.9 58.8 ± 0.2 
0.5 57.9 ± 0.3 56.2 ± 0.2 
1 56.5 ± 3.9 53.8 ± 3.2 
 
The exact physicochemical interaction between proteins and nanoparticles remains not fully 
understood (Fleischer and Payne, 2012; Lundqvist et al., 2011; Lundqvist et al., 2008; Lynch et 
al., 2007). Simple ionic interactions are not the driving force for the nanoparticle-protein 
complex, as the proteins showed to be adsorbed on anionic surfaces in conditions above their 
isoelectric point, meaning that the protein itself was also negatively charged. If ionic interactions 
are responsible for the nanoparticle-protein interaction negatively charged proteins could not 
adsorb at SDS-NP or sodium cholate-NP. It has been discussed that hydrophobic interactions are 
responsible for the PLGA-protein complex (Chen et al., 2004; Rahman et al., 2013). A 
prediction, as to how high an adsorption of a protein is to a given nanoparticle formulation cannot 
be made, as of now each protein must be tested individually for each nanoparticle formulation. 
The fact that proteins adsorb at the surface of nanoparticles must be carefully considered before 
administration of nanoparticles in-vivo, as proteins in the blood can interact with the 
nanoparticles.  
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Also, experiments with nanoparticles in the cell culture must be revisited, when surface 
modifications are responsible for certain interactions with cells, e.g. uptake in cells. The 
conditions in-vivo are much more complex and adsorption of proteins onto the surface of 
nanoparticles can change their properties and thereby change their interactions with cells. Protein 
free media or even PBS as media should therefore not be used for nanoparticle cell culture 
experiments as results are most likely not applicable for in-vivo conditions. 
 
4.2.1.7 Stability of nanoparticles 
The o/w-NP were tested regarding their stability to determine, if fresh samples must be produced 
for further experiments or if o/w-NP were sufficiently stable over a prolonged period of time.  
The o/w-NP formulations were stored at different temperatures, and either as nanoparticle 
suspensions or as freeze dried nanoparticles. All samples were stable over 4 weeks regarding 
their particle size properties when stored at 4 °C as nanoparticle suspensions (Table 19). 
However, the nanoparticle suspensions were not stable when stored at -20 °C or 20 °C. 
Surprisingly, the nanoparticle suspensions were not completely re-dispersible by simple shaking 
after storage at -20 °C, as aggregates were clearly visible. The nanoparticle suspensions were re-
dispersible by ultrasonication for 5 minutes. However, this was not necessary for the original 
nanoparticle suspension before storage.  
Ultrasonication can be harmful to proteins, therefore it should be avoided for specific 
nanoparticle formulations, as mild processing conditions were a major driver for the development 
of these nanoparticles. That is why the samples are listed as instable, when stored at -20 °C.  
Freeze dried nanoparticles were stable over 4 weeks of storage at 4 °C and easily re-dispersible, 
except for the CTAB-NP. Trehalose was added to the nanoparticle suspension at a concentration 
of 5% prior freeze drying as a cryoprotectant.  
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Table 19: Stability of o/w-nanoparticles over 4 weeks storage; Samples were stored either as 
nanoparticle suspension at -20 °C, 4 °C or 20 °C or as freeze dried nanoparticles at 4°C. (-) 
indicates that sample was not redispersible or aggregation occurred  
Nanoparticle formulation Nanoparticle suspension Freeze dried nanoparticles 
 -20 °C 4 °C 20 °C 4 °C 
PVA-NP - 146.9 nm - 139.3 nm 
Tween 20-NP - 183.2 nm - 173.3 nm 
Sodium-cholate-NP - 126.7 nm - 164.6 nm 
SDS-NP - 211.9 nm - 187.4 nm 
CTAB-NP - 220.7 nm - - 
 
 
4.2.1.8 Characterization of Lipopolysaccharides loaded nanoparticles 
The findings about the nanoparticles with the surface adsorbed protein with different surfactants 
showed a simple method to prepare protein loaded, polymeric nanoparticles. Derived from this 
method, LPS-NP were prepared, by using the emulsification-evaporation method. LPS-NP were 
developed to be used as an adjuvant formulation to be applied in combination with an antigen. 
Here, LPS was added to the outer water phase during the emulsification-evaporation method, 
technically acting as the surfactant, leading to polymeric nanoparticles with surface adsorbed 
LPS. LPS-NP are currently investigated regarding its potential as vaccine adjuvants (Gómez et 
al., 2008). In this work, a novel preparation of the LPS-NP was employed. 
LPS-NP were prepared by a simple emulsification-evaporation method and the active ingredient 
LPS also operated as the surfactant so that no additional surfactant was necessary. The resulting 
LPS-NP had a LPS concentration of 1 mg/ml and a PLGA concentration of 2.5 mg/ml. As the 
quantitative measurement of LPS is normally very complex (Binding et al., 2004) an indirect 
method was applied to quantify the amount of LPS on the nanoparticles. FITC-labeled LPS was 
used to prepare LPS-NP, afterwards the nanoparticles were centrifuged and the supernatant was 
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tested regarding its FITC-LPS content. It was observed that almost 70% of the LPS was bound to 
the nanoparticles (Table 20). The prepared LPS-NP had a particle size with a mean diameter of 
around 200 nm. This particle size was desired as LPS-NP in that size range showed an improved 
immune response in mice in previous studies (Gómez et al., 2008). The L2 formulation was 
subsequently used as an adjuvant formulation in combination with CpG in the mice studies, as 
LPS and CpG are PAMPs and therefore TLR-4 receptor agonist that induce dendritic cell 
maturation and T-lymphocytes activation.  
 
Table 20: Particle size and loading rate of LPS-NP (mean ± SD; n = 3) 
Sample LPS formulation  Mean diameter [nm] Loading rate [%] 
L1 2 ml of LPS-solution 
[1 mg/ml] 
227 ± 13 - 
L2 4 ml of LPS-solution 
[1 mg/ml] 
175 ± 8 - 
L3 3.8 ml of LPS-
solution [1 mg/ml] + 
0.2 ml FITC-LPS 
179 ± 2 68 ± 2 
 
 
4.2.2 Cell culture experiments 
The investigation of toxicity of nanoparticles was conducted using a RAW 264.7 cell line. The 
uptake as well as the localization of the nanoparticles in the cells following incubation was also 
investigated. 
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4.2.2.1 Cytotoxicity of nanoparticles  
The cell viability after incubation with the o/w-NP was tested using a MTT-assay as described in 
chapter 3.6.2.1. It was observed that the anionic SDS-NP and sodium cholate-NP were untoxic as 
the cell viability was between 80-100% regardless of the applied nanoparticle concentration (Fig. 
30). The same untoxic effect on the cell viability was seen when using the nonionic PVA-NP. 
The cell viability was above 90% for all nanoparticle concentrations that were tested. However, 
when testing the nonionic Tween 20-NP, a toxic effect was clearly visible. For a Tween 20-NP 
concentration of 3 mg/ml a cell viability of less than 20% was determined. CTAB-NP were even 
more toxic compared to the Tween 20-NP as a cell viability of less than 20 % was detected when 
using a CTAB-NP concentration of only 0.3 mg/ml.  
It must be kept in mind that different surfactant concentrations were used for the preparation of 
each formulation (Table 15). This partly explains why the SDS-NP do not show any toxicity as 
the used SDS concentration in the nanoparticle preparation was just 0.01%. Tween 20 on the 
other hand was used at a concentration of 1%.  
It can be concluded that for further studies a nanoparticle concentration of 0.1 mg/ml is suitable 
for experiments as problems regarding the cell viability are minimal.  
However, Tween 20-NP and CTAB-NP did show a toxic effect on the cells. This toxicity has to 
be carefully monitored for the in-vivo studies. On the other hand, a mild toxicity might be 
beneficial for immunization studies as it could attract macrophages and dendritic cells.  
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Fig. 30: Cell viability of o/w-NP formulations using concentrations of 0.03 mg/ml – 3 mg/ml 
(mean ± SD; n = 3) 
 
 
4.2.2.2 Uptake of nanoparticles in macrophages 
The uptake of o/w-NP into macrophages was measured as described in chapter 3.6.2.2, after the 
particles were stained with Nile red. All five available o/w-NP formulations were tested to 
investigate, if the surfactant has an impact on the cell uptake. Furthermore, it must be considered 
that the adsorbed OVA on the surface also influence the uptake of the o/w-NP into the cells. The 
uptake studies were conducted using the RAW 264.7 macrophage cell line.  
In preliminary tests it was seen that an incubation period of 2 h is beneficial for investigation as 
the uptake of the o/w-NP is nearly complete after 2 h (Fig. 62). A slight increase can be observed 
after 2 h, but the standard deviation increases by 3-5 times at 4-8 h of incubation time, making 
the results after 2 h much more reliable.  
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Therefore, each o/w-NP formulation was tested for its uptake into RAW 264.7 cells after 2 h. 
The uptake of the nonionic and anionic o/w-NP formulation were similar with an uptake of 37 -
44% (Fig. 31). The Tween 20-NP had the highest uptake of 44% ± 6%. PVA-NP had an uptake 
of 39% ± 1%, sodium-cholate-NP of 39% ± 2% and SDS-NP of 38% ± 8%. The uptake of the 
cationic CTAB-NP formulation was significantly lower compared to the other formulations. The 
uptake of the CTAB-NP was 33% ± 1%.  
 
 
Fig. 31: Uptake of o/w-NP in RAW 264.7 cells after 2 h (mean ± SD; n = 3; *p < 0.05 compared 
to CTAB, Kruskal-Wallis one way analysis of variance on ranks followed by Student-Newman-
Keuls test) 
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4.2.2.3 Localization of nanoparticles in cells (CLSM) 
To investigate the localization of the nanoparticles in RAW 264.7 cell, CLSM was applied to 
nanoparticles that were previously stained with Nile red. 
It is clearly visible that for all o/w-NP formulations the particles are located inside the cells as 
opposed to the cell membrane (Fig. 32). It can be concluded that, the o/w-NP have been taken up 
into the RAW 264.7 cells. This is important as the results of the uptake studies do not prove that 
the o/w-NP are really inside the cells. The uptake study only gave a quantitative analysis of the 
cell associated particles, while the location of the particles remained unknown, because the 
uptake study only quantified how much of the nanoparticles was adsorbed at the cell membrane 
or taken up into the cells in total. A differentiation of whether the nanoparticles are located at the 
cell membrane or inside the cells was not investigated by the uptake study. However, with the 
CLSM images a qualitative characterization about the localization of the cell associated particles 
was possible and it could be concluded that the o/w-NP were inside the cells. 
The Nile red-NP are accumulating as red dots in the cells. This most likely means that the 
nanoparticles are not located dispersed in the cytosol, but inside lysosomes and endosomes.  
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Fig. 32: CLSM images of RAW 264.7 cells after incubation with different nanoparticle 
formulations: a) cells without nanoparticles as control b) PVA-NP c) Tween 20-NP d) Sodium 
cholate-NP e) SDS-NP f) CTAB-NP; Nanoparticles were stained with Nile red (red), cell 
membrane was stained with concanavalin A (green) and cell nucleus was stained with DAPI 
(blue). The scale bar represents 10 µm. 
 
4.2.3 In vivo studies 
The ability of proteins to adsorb at the o/w-NP surface was shown in this work. The surface of 
the nanoparticles was modified, depending on the surfactant that was used. The different 
formulations were characterized amongst other things regarding their loading rate of the proteins 
and their ability to be taken up by cells. LPS-NP already showed the potential to increase an 
immune response (Gómez et al., 2008; Gómez et al., 2009), therefore the LPS-NP prepared in 
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this work with an emulsification-evaporation method were tested regarding their ability to 
influence the immune response. 
To investigate the adjuvant effect of the o/w-formulations in-vivo studies were conducted. IgG 
titres were examined to quantify the immune response after immunization. OVA was used as a 
model antigen, as it already proved to be a suitable antigen in mice for immunization studies 
(Kasturi et al., 2011) and the IgG concentration was tested using an ELISA-Kit specifically for 
Anti-OVA IgG. Blood samples were drawn on study day 0, study day 20 and study day 35. The 
first blood sample was simply to control, if the antibody titer was not elevated before the start of 
the immunization. On day 20 a low IgG antibody titre was expected, but conclusions about the 
adaptive immune response cannot be made, as the immune effects are mainly results of the innate 
immune system. Essential for an evaluation of the adaptive immune response are the IgG-titres at 
study day 35. After the second vaccination IgG is being released by B-cells, and the 
concentration reduces very slowly over a prolonged period of time (Dario-Becker, 2013; Schütt 
and Bröker, 2009).  
 
4.2.3.1 Carbopol and ovalbumin loaded nanoparticles in mice 
In the first two in-vivo studies, the nonionic OVA loaded o/w-NP formulations (Tween 20-NP 
and PVA-NP) were tested regarding their immune response. Carbopol was added as an additional 
adjuvant as it was unknown, if the o/w-NP itself would elicit an antibody response that is 
measurable. In both studies 6 groups were tested. The first three groups were OVA loaded 
Tween-20 NP, OVA loaded PVA-NP and PBS with OVA. The other three groups were exactly 
the same besides that they also contained Carbopol.  
It was expected that there would be no Anti OVA IgG detected on study day zero (SD 0) before 
the first immunization as the mice did not come in contact with OVA. The food was strictly OVA 
free.  
On SD 20 the IgG titres may already be elevated a little bit as the IgG production starts typically 
two weeks after the first immunization (Schütt and Bröker, 2009). For non-live, attenuated 
vaccines, one vaccination is not enough, therefore a second vaccination was performed at SD 20 
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and blood samples were drawn on SD 35 and SD 42. The IgG titres were clearly elevated on SD 
35 and SD 42 (Fig. 33). Moreover, since no IgG was found on SD 0, all mice were evaluable for 
this study.  
 
 
Fig. 33: Serum IgG-titres of mice after immunization – in vivo study I (mean ± SD, n=4-5), 
vaccinations on SD 0 and SD 20 
 
A statistical difference between the groups could not be detected. Differences within the groups 
were not surprising as the results of in-vivo immunization studies often appear with relatively big 
standard deviations. However, when examining each group individually, it was surprising that in 
every group some mice elicit a strong immune response and some no immune response at all 
(Fig. 34). Even though differences within each groups were expected, it was not expected that 
some mice showed an immune response following immunization and some did not, when 
examining the same group. A statistical difference could not be found, because a high variability 
of the immune response within the groups was detected and a low test population was available. 
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Fig. 34: Serum IgG-titres of each mouse after study day 35 – in vivo study I (n= 4-5) 
 
The highest Anti OVA IgG titres were detected for PVA-NP with Carbopol followed by the 
PVA-NP group. Surprisingly, the control group OVA in PBS with Carbopol elicited a higher 
immune response than the Tween-20 NP with Carbopol group. However, a statistical difference 
was not observed as the differences within the groups were considered too high.  
Therefore, a second in-vivo study was performed using the same protocol. 
Here, the results were in stark contrast to those in the first immunization study. The Tween 20-
NP group and the Tween 20-NP with Carbopol group showed the highest IgG titres on SD 35 and 
SD 42, followed by the PBS with OVA and Carbopol group. Surprisingly, the PVA-NP with 
Carbopol group did not just elicit a smaller immune response than the PBS with OVA and 
Carbopol group, but also it did have smaller IgG titres than the PVA-NP group without the 
additional Carbopol (Fig. 35). However, a statistical difference comparing each group was not 
found. 
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As Carbopol is a well-known, widely tested adjuvant it cannot be explained why the group 
without Carbopol should have elicited a higher immune response, when using OVA loaded PVA-
NP.   
 
 
Fig. 35: Serum IgG-titres of mice after immunization – in vivo study II (mean ± SD, n= 5), 
vaccinations on SD 0 and SD 20 
 
When examining each mouse within each group a similar conclusion as to the first immunization 
study can be made. In every group, except for the Tween 20-NP group, there were mice that 
showed an immune response and some that did not (Fig. 36). As BALB/c mice are a widely used 
mice strain for immunization studies these results are very surprising. Differences within each 
groups are expected, but not a qualitative difference within a group as to if there is an immune 
response or not. 
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Fig. 36: Serum IgG-titres of each mouse after study day 35 – in vivo study II (n= 5) 
 
These results suggest that there may have been a technical error during the immunization. 
Problems with the mixing of the Carbopol and nanoparticle formulation and erroneous 
administration of the samples in the neck fold might result in variable IgG titres.  
Therefore, further in-vivo studies are necessary to determine, if the o/w-NP do or do not have an 
adjuvant effect. In-vivo study I and in-vivo study II were inconclusive.  
 
4.2.3.2 In vivo testing of different adjuvants 
In the next in-vivo study different adjuvant formulations were tested. CFA/IFA is a well-known 
adjuvant that elicits very high antibody titres, but is not used in humans or farm animals due to 
toxicity issues. As the use of this adjuvant is very dangerous, the mice were anaesthetized with 
isofluran before immunization. CFA/IFA was used as a positive control group. The test groups 
were LPS-NP with CpG and LPS in solution with CpG. PBS with OVA was used as another 
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control group to see if the test groups show a beneficial influence regarding the immune response 
in mice following their administration.  
The diagram of the IgG antibody response shows the typical process of an immunization study 
(Fig. 37). The IgG titres are at 0 U/ml before the first immunization for all formulations, meaning 
that the mice did not possess any Anti OVA IgG before the study. Before the second 
immunization at SD 20, the IgG titres are not higher than 5 × 106 for any group. This is also 
typical for immunization studies, where the immunizations are three weeks apart. Following the 
first immunization IgG starts to be build up after two weeks, but a fast decrease of IgG occurs 
afterwards (Schütt and Bröker, 2009). After the second immunization, a high IgG concentration 
is immediately existent that decreases very slowly over a long period of time, depending on the 
intensity of the immune response. 
As expected, the CFA/IFA formulations showed the highest immune response (Fig. 37). The 
difference to the other groups was significant. In addition, the LPS-NP group was significantly 
better than the LPS and PBS group regarding its antibody response.  
Here, it was shown that the LPS-NP caused a significantly higher antibody response than the LPS 
solution, meaning that the TLR-4 agonist LPS is taken up by dendritic cells and macrophages to 
provoke a strong immune response. LPS is one class of PAMP that leads to the maturation of 
dendritic cells and subsequently to the activation of T-lymphocytes (Gómez et al., 2009).  
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Fig. 37: Serum IgG-titres of mice after immunization – in vivo study III (mean ± SD, n= 5-6; 
*p < 0.05 compared to PBS and LPS + CpG, Kruskal-Wallis one way analysis of variance on 
ranks followed by Student-Newman-Keuls test) 
 
When comparing the IgG titres of each mouse within each group, it is clearly visible that this 
immunization study is much more viable than the first two immunization studies (Fig. 34, Fig. 
36, Fig. 38). The elicited antibody response is much more homogenous in in vivo study III 
compared to the first two in-vivo studies.  
This strongly suggests that in the first two immunization studies a methodical error occurred 
during the immunization.  
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Fig. 38: Serum IgG-titres of each mouse after study day 35 – in vivo study III (n= 5-6) 
 
It can be concluded that LPS-NP are favorable compared to LPS in solution. The immune 
response in the LPS-NP and LPS in solution group is of course also a consequence of the CpG, 
but since it was present in both groups, the difference between the groups can be attributed to the 
usage of nanoparticles. The nanoparticles are able to get inside the cells, TLR are located at the 
cell surface as well as inside cells at endosomes. The application of LPS-NP is advantageous as 
LPS does not only fulfill its agonistic properties on TLR on the cell surface, but also inside the 
cells on endosomes following a better uptake into the cells with the nanoparticles. 
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4.2.3.3 Lipopolysaccharides loaded nanoparticles and ovalbumin loaded 
nanoparticles in mice 
The next in-vivo study was performed to test the different OVA loaded o/w-formulations 
regarding their ability to enhance the immune response compared to LPS-NP with OVA. As 
OVA is located onto the surface of the o/w-NP, it is fast released and can be recognized 
immediately by cells of the immune system, like dendritic cells and macrophages. Due to its 
adsorption on nanoparticles, OVA might even be better taken up by cells compared to OVA 
alone.  
It must be noted that the loading rate of the different o/w-NP formulations were different. Since 
no washing step was performed, all formulations had the same OVA amount within one 
nanoparticle suspension, but the ratio of OVA loaded on the o/w-NP and OVA in solution was 
different, e.g. for the CTAB-NP no loading was observed.  
All o/w-NP formulations that were injected also contained LPS-NP and CpG in the same 
concentration as in the control group. 
As already shown in the previous in-vivo studies, the time-diagram of the antibody response had 
a typical progress (Fig. 39).  
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Fig. 39: Serum IgG-titres of mice after immunization – in vivo study IV (mean ± SD; n= 5-6) 
 
The CTAB-NP showed the highest immune response following administration in mice (Fig. 40). 
The antibody response was significantly higher compared to all other groups. The OVA loaded 
Tween 20-NP and OVA loaded PVA-NP elicited a significantly higher immune response 
compared to the control group PBS without additional LPS, but the difference compared to the 
control group with LPS-NP was not significant. The anionic o/w-NP formulations did not 
provoke a higher immune response than the PBS control group.  
For the SDS-NP it can be assumed that the SDS linearizes the protein, therefore reducing its 
immunogenic properties. It was expected that significantly higher immune response would be 
produced by the other formulations, because of the good cell uptake of the PVA-NP, Tween 20-
NP and sodium cholate-NP into macrophages coupled with high loading rates for these o/w-NP 
formulations. The loading of the nonionic o/w-NP was relatively high (71% - 83%). In cell 
culture studies it was already shown that nonionic o/w-NP can be taken up by cells and that they 
are located inside the cells. However, a significant effect regarding their antibody response in 
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mice was not observed. It can be hypothesized that the cell uptake and delivery of the protein into 
the cells of the immune system is not the mode of action here, but that the toxic properties of the 
nanoparticles play an important role.   
 
 
Fig. 40: Serum IgG-titres of mice after immunization at SD 35 – in vivo study IV (mean ± SD; 
n= 5 – 6; *p < 0.05 compared to I, $p < 0.05 compared to VII, Kruskal-Wallis one way analysis 
of variance on ranks followed by Student-Newman-Keuls test) 
 
 
The high immune response of the CTAB-NP might be explained by their toxic characteristics. As 
previously described, the CTAB-NP and Tween-NP showed the highest toxicity in the cell 
culture model using RAW 264.7 cells. Those two formulations showed the highest antibody 
response after immunization in mice. The Tween-NP showed a good loading with OVA, but the 
CTAB-NP were not loaded at all with OVA. Therefore, the effect of an enhanced cell uptake via 
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nanoparticles of OVA cannot be the reason for the high immune response. More likely is that, 
because of its toxic potential, cells of the immune system are being released to the injection site, 
making it more probable for OVA to be processed. This is a mode of action similar to other 
adjuvants, where the cell uptake is not the primary concern. Many adjuvants induce an 
inflammation, e.g. CFA/IFA and Alum, thereby activating the innate immune system and 
subsequently leading to adaptive immunity in combination with an immunogenic. Therefore, the 
activation of the innate immune system by the nanoparticles might be responsible for the higher 
immune response compared to the control group. 
 
4.2.3.4 Influence of nanoparticle concentration on immune response in mice 
In the previous in-vivo study it was observed that CTAB-NP had a significant influence on the 
immune response after immunization in mice in combination with LPS-NP and OVA. The 
nonionic o/w-NP formulations also elicited high immune responses, but a statistical difference 
was not obtained. The anionic o/w-formulations showed the smallest antibody response; therefore 
further testing was conducted without these anionic o/w-NP formulations.  
Here, the influence of the nanoparticle concentration was supposed to be determined. As in the 
previous study, all formulations contained LPS-NP and CpG in the same concentration as in the 
control group. The concentration of the PLGA-NP was varied, but the surfactant content stayed 
the same for each o/w-NP formulation. A difference in the immune response could therefore be 
attributed to the nanoparticles and not to the “free” surfactant in solution.  
As already shown in the previous in-vivo studies, the time-diagram of the antibody response had 
a typical progress (Fig. 41). 
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Fig. 41: Serum IgG-titres of mice after immunization – in vivo study V (mean ± SD, n= 4-5) 
 
When comparing the IgG titres at SD 35, it can be clearly seen that the dose of the nanoparticles 
has an effect on the immune response (Fig. 42). 
Groups II-IV with a nanoparticle concentration of 2 mg/ml for each o/w-NP formulation have the 
smallest IgG titres, followed by the formulations with 10 mg/ml, while formulations with 50 
mg/ml nanoparticles provoked the highest immune response. 
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Fig. 42: Serum IgG-titres of mice after imm 
unization at study day 35 – in vivo study V (mean ± SD, n= 4-5; *p < 0.05 compared to LPS-NP, 
Kruskal-Wallis one way analysis of variance on ranks followed by Student-Newman-Keuls test) 
 
When comparing the CTAB-NP at different concentrations with each other it can be observed 
that, when using the highest nanoparticle concentration (50 mg/ml), a statistical difference to the 
other used concentrations (10 mg/ml and 2mg/ml) and to the control group is existing (Fig. 43). 
As already seen in the previous study, also the CTAB-NP formulation with 10 mg/ml elicits a 
higher antibody response than the control group. The results of the previous study could be 
confirmed in that regard.  
This clearly means that the concentration of the nanoparticles has an influence on the antibody 
response in mice. As discussed earlier, an inflammatory effect might be the cause for the immune 
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response following immunization with CTAB-NP. Therefore, a higher immune response with a 
higher nanoparticle concentration is comprehensible. 
The inflammatory effect of CTAB-NP was visible at a concentration of 50 mg/ml as four out of 
five mice had a mild inflammation at the injection site. Two weeks after the immunization in the 
neck fold the immunization was still visible on the neck. This suggests that a strong inflammation 
occurred during immunization, making the CTAB-NP at such high concentrations inapplicable as 
adjuvants, as safety and tolerability is of utmost importance for adjuvants. Adjuvants that on the 
one hand elicit a very strong antibody response and on the other hand are toxic or highly 
inflammatory are not suitable for parental application. An example for this would be CFA/IFA, 
high antibody titres can be obtained, when a vaccine is administered with CFA/IFA, but due to 
toxicity issues CFA/IFA is only used for research and development.  
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Fig. 43: Serum IgG-titres of mice after immunization at study day 35 – in vivo study V – CTAB-
NP at different concentrations (mean ± SD, n= 4-5; *p < 0.05 compared to LPS-NP, Kruskal-
Wallis one way analysis of variance on ranks followed by Student-Newman-Keuls test) 
 
The PVA-NP showed a similar behavior as the other o/w-NP formulations, as the IgG titres at SD 
35 increased with increasing concentrations of the nanoparticles (Fig. 44). The PVA-NP with the 
highest nanoparticle concentration (50 mg/ml) provoked an antibody response at SD 35 that was 
significantly higher compared to the control group. The titres caused by PVA-NP at the other 
concentrations were also higher than the control group, but a statistically significant difference 
was not observed. The results of the previous study could be confirmed in that regard. 
An inflammation at the injection site was not visible for any concentration of PVA-NP that was 
used for this immunization study, making the PVA-NP better tolerable to the CTAB-NP at the 
highest concentration, even though it must me noted that the CTAB-NP at 50 mg/ml provoked a 
much higher immune response than the PVA-NP. 
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Fig. 44: Serum IgG-titres of mice after immunization at study day 35 – in vivo study V – PVA-NP 
at different concentrations (mean ± SD, n = 5; *p < 0.05 compared to LPS-NP, Kruskal-Wallis 
one way analysis of variance on ranks followed by Student-Newman-Keuls test) 
 
The Tween 20-NP showed a similar behavior as the other o/w-NP formulations, as the IgG titres 
at SD 35 increased with increasing concentrations of the nanoparticles (Fig. 45). Tween-NP at a 
concentration of 50 mg/ml provoked an immune response that was significantly higher than the 
LPS-NP (control group). At the other concentrations of the Tween 20-NP a significant difference 
compared to the control group was not observed, even though a slight increase of the immune 
response was visible when comparing the Tween 20-NP with the control group. The results of the 
previous study could be confirmed in that regard. 
Tween 20-NP like the also non-ionic PVA-NP did not induce any visible inflammation at the 
injections site, meaning that they are superior to the CTAB-NP regarding their safety and 
tolerability.    
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Fig. 45: Serum IgG-titres of mice after immunization at study day 35 – in vivo study V – Tween 
20-NP at different concentrations (mean ± SD, n = 5; *p < 0.05 compared to LPS-NP, Kruskal-
Wallis one way analysis of variance on ranks followed by Student-Newman-Keuls test)  
 
 
The in-vivo studies revealed insight into the strength of immune responses following the 
application of different adjuvants.  
Surprisingly, the first two in-vivo studies were inconclusive due to huge variations within each 
group regarding their antibody response after immunization.  
The testing of different adjuvant formulations revealed that LPS-NP in combination with CpG 
are beneficial to LPS in solution in combination with CpG. This is of particular interest as TLR-4 
agonists pose as an intriguing way to trigger a strong immune response to obtain adaptive 
immunity. LPS itself is too toxic to be used in humans, but similar TLR-4 agonists are already 
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being tested in clinical trials. Preparation of TLR-4 agonists with nanoparticles might be 
beneficial in terms of the adjuvant effect as the LPS-NP showed an improved immune response 
compared to the LPS in solution. Furthermore, it was seen that CFA/IFA showed significantly 
higher antibody responses than the LPS-NP, but the CFA/IFA formulation was just tested to have 
a positive control. Due to toxicity issues CFA/IFA is obsolete, although very high antibody 
responses can be produced with CFA/IFA.  
The experiments with the five different o/w-NP formulations revealed that the CTAB-NP elicit 
the highest antibody response. This was particularly surprising as it was previously observed that 
no OVA was adsorbed at the surface of the CTAB-NP, meaning that the uptake into cells with 
the nanoparticles was not the mode of action here. Besides, CTAB-NP showed to have the lowest 
uptake rate into cells in cell culture experiments conducted with RAW 264.7 cells. Rather than a 
drug targeting with CTAB-NP, an activation of the immune system due to inflammation seems to 
be responsible for the high immune response. This hypothesis is supported by the fact that the 
antibody response increases with higher CTAB-NP concentration and inflammation was visible 
at the injection site for CTAB-NP with the highest nanoparticle concentration. 
The antibody response for the nonionic o/w-NP formulations was also slightly increased 
compared to the control group. The nonionic o/w-NP formulations did not alter the immune 
response compared to the control at a concentration of the nanoparticles of 10 mg/ml. A 
significant difference in the antibody response for the nonionic o/w-NP formulations was just 
observed at the highest nanoparticle concentration, suggesting that a dose-dependent 
inflammatory effect may also be the mode of action here. Even for low dosage nanoparticle 
formulations a high loading rate, similar to high dosage nanoparticle formulations, was observed, 
which leads to the assumption that not the loading rate, but the nanoparticle dosage is deciding 
for the immune response. 
It has been reported that nanoparticles and microparticles with conjugated antigens show a 
stronger immune response than soluble antigen (Kasturi et al., 2011; Singh et al., 2007). In these 
studies a size dependent effect was seen, as particles smaller than 10 µm showed a significantly 
higher immune response (Singh et al., 2007). Nanoparticles in a size range of 50 – 200 nm 
elicited a stronger immune response than larger and smaller particles (Kuroda et al., 2013). It has 
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also been previously investigated that dendritic cells are able to internalize PLGA-NP (Hamdy et 
al., 2011).  
However, nanoparticles used in those studies were prepared by a double-emulsion method and it 
was postulated that the antigen is encapsulated inside the nanoparticle (Blanco and Alonso, 1997; 
Hamdy et al., 2011; Kasturi et al., 2011; Lamprecht et al., 1999). In this work we showed that the 
protein is not located inside the nanoparticles, but adsorbed at the particle surface. This does not 
contest the findings of the other studies, but the mode of action must be revisited, as phagocytosis 
of the nanoparticles with the encapsulated antigen was considered crucial for the stimulation of 
the immune system (Kuroda et al., 2013).  
LPS loaded nanoparticles combined with antigen showed a proinflammatory effect, which 
ultimately led to an increase of the immune response in mice studies (Demento et al., 2009). In 
the study of Demento et al. it was also hypothesized that the antigen encapsulated in a 
nanoparticulate carrier was better internalized into the dendritic cells.  
However, the strongest immune response in this work was observed for CTAB-NP, which did not 
have OVA adsorbed at the particle surface. OVA was dissolved in the nanoparticle suspension, 
suggesting that an uptake into the cells with the nanoparticle was not important for the strong 
antibody response. Moreover, it can be hypothesized that the CTAB-NP activate the immune 
system due to their toxic surface properties. The toxicity has been previously discussed (see 
4.2.2.1).  
The potential of nanoparticles as vaccine adjuvants has already been tested in-vivo and proven 
successful in regard to a significantly higher immune response compared to soluble antigen 
(Demento et al., 2009; Hamdy et al., 2011; Kasturi et al., 2011). However, a comprehensive 
understanding about the mode of action of nanoparticles as vaccine adjuvants is still not 
available.  
Further testing would be required to investigate the exact mode of action of the o/w-NP, prepared 
in this work. The nonionic o/w-NP were only an improvement at a nanoparticle concentration of 
50 mg/ml, regarding their adjuvant capabilities. The CTAB-NP were showing an adjuvant effect 
at lower concentrations, but those nanoparticles are most likely not suitable for vaccinations, due 
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to their toxic potential. An inflammation was visible at the injection site in the mice studies 
conducted in this work, when using CTAB-NP. 
PLGA nanoparticles already showed to increase the immune response as vaccine adjuvants in 
mice. However, further studies are necessary, to determine if the nanocarriers are an 
improvement to alternative adjuvant systems as PLGA-NP are very expensive and the toxic 
effects following administration might outweigh the benefits.  
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4.3 Microparticles prepared with double-emulsion-solvent-extraction 
method 
All microparticle samples were prepared using the double-emulsion-solvent-extraction method, 
because it is a suitable technique to encapsulate hydrophilic drugs like proteins into 
microparticles, and it can be easily performed in the laboratory without needing costly 
equipment. 
Microparticles have long been investigated for their adjuvant potential (O’Hagan and Singh, 
2003), in the present work different microparticle formulations were characterized regarding their 
physicochemical characteristics. 
All particle sizes are being portrayed as d50 values. All microparticle formulations were loaded 
with BSA as a model antigen. 
 
4.3.1 Physicochemical characterization of microparticle properties  
4.3.1.1 Influence of polymer and surfactant on particle size and loading rate 
PLGA is commonly used as a polymer for micro- and nanoparticulate carriers for parental use, as 
its biocompatibility and biodegradability has been observed and its use is approved for humans 
by the FDA (Jain, 2000). 
When applying the double-emulsion method as described in chapter 3.3.1 with different PLGAs, 
but not changing anything other in the setting of the preparation, different results regarding the 
particle size and the encapsulation efficiency (Table 21) are obtained. In this work, the 
microparticles were prepared under the same conditions to investigate the influence of the 
polymer on the process.  
The particle size increases when the molecular mass of the used polymer increases. RG 502 H 
has the smallest molecular mass of the tested polymer and yields the smallest particle size. This 
effect can be attributed to the higher viscosity of polymers with a higher molecular mass, e.g. the 
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inherent viscosity of RG 502 H is 0.16 - 0.24 dl/g, of RG 503 H 0.32 – 0.44 dl/g, of RG 504 H 
0.45 – 0.60 dl/g and of RG 505 0.61 – 0.74 dl/g. When using the same concentrations the 
inherent viscosity is proportional to the viscosity. As always the same amount of each polymer 
was used it can be assumed that the viscosity of the polymer phase in the manufacture of the 
microparticles increases from RG 502 H to RG 505. 
The only sample in which the particle size does not increase when the viscosity increases is 
RG 505, but here the properties of the polymer are a little different to the other tested PLGAs as 
the end groups are not carboxylated. Therefore, the conditions are not the same as this structural 
difference also leads to different behavior of the polymer in solution, e.g. regarding its ability to 
accumulate on interfaces. 
 
Table 21: Particle size of microparticles prepared with different PLGA’s (mean ± SD, n = 3) 
Polymer D10 [µm] D50 [µm] D90 [µm] Encapsulation 
efficiency [%] 
RG 502 H 13.7 ± 0.6 34.6 ± 6.1 92.0 ± 10.9 54.4 ± 2.5 
RG 503 H 11.3 ± 0.9 59.9 ± 1.0 87.9 ± 0.9 42.7 ± 1.5 
RG 504 H 16.7 ± 15.2 65.3 ± 19.7 95.7 ± 18.3 65.9  ± 10.5 
RG 505 10.6 ± 2.0 56.3 ± 13.1 86.7 ± 21.8 55.6 ± 3.7 
 
 
The microparticle formulations were further tested regarding their encapsulation efficiency. The 
microparticles were loaded with BSA. When comparing the different PLGAs with each other no 
clear correlation to the viscosity or the particle size was observed (Fig. 46). The encapsulation 
efficiencies were between 42% - 66%, if no Span 60 was added to the oil phase during the 
preparation. A statistical difference regarding the encapsulation efficiency was not observed 
when comparing the samples without Span 60.  
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Surprisingly, the samples that were prepared with Span 60 showed a very low encapsulation rate, 
although the other processing conditions remained the same. The same polymers were used to 
investigate the influence of Span 60.  
The encapsulation efficiency was below 7.5 % for all formulations. Theoretically it was assumed 
that Span 60 would stabilize the interface between the inner water phase and the oil phase, and 
thereby prevent leaking of the protein. However, it was observed that the opposite effect was 
happening leading to very low encapsulation efficiencies, when using Span 60 in the oil phase.  
Therefore, Span 60 was not used for further studies as poor encapsulation efficiencies are not 
acceptable, especially when working with proteins, which are in general very expensive. 
 
 
Fig. 46: Influence of Span 60 in the inner water phase on the encapsulation efficiency of 
microparticles prepared with different PLGA’s (mean ± SD, n = 3) 
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4.3.1.2 Influence of emulsification process on particle size and loading rate 
The conditions of the preparation method were further altered regarding the emulsification 
process. The rest of the conditions were kept constant, using RG 502 H as a polymer, and no 
Span 60. 
First, the influence of the emulsification of the double-emulsion was investigated. The conditions 
for the first emulsifications step were kept constant for these experiments. Using different stirring 
speeds from 500 rpm – 1000 rpm in the second emulsification step, it was observed that the 
particle size decreased with increasing stirring speed. The first emulsification step is the deciding 
factor for the particle size, but apparently, the second emulsification step is also important, as 
higher stirring speeds resulted in smaller particles (Table 22).  
 
Table 22: Influence of stirring speed of propeller stirrer during emulsification of double 
emulsion on particle size and encapsulations efficiency (mean ± SD, n = 3) 
Stirring speed of Propeller 
stirrer [rpm] 
D10 [µm] D50 [µm] D90 [µm] Encapsulation 
efficiency [%] 
500 15.3 ± 0.3 64.5 ± 0.3 115.0 ± 9.2 41.7 ± 0.8 
850 13.7 ± 0.6 34.6 ± 6.1 92.0 ± 10.9 54.4 ± 2.5 
1000 5.0 ± 1.6 24.6 ± 7.2 52.0 ± 9.5 53.5  ± 1.6 
 
 
Furthermore, the influence of the first emulsification step in the double-emulsion method was 
tested regarding its influence on the particle size and the loading rate (Table 23). The conditions 
of the other parameters were kept the same; the second emulsification step was performed by 
constant conditions using a propeller stirrer.  
Three different devices were tested for the first emulsification process, ultrasound using a 
Sonicatior, and two Ultra turrax devices (UT 8 and UT 18). Both Ultra turrax devices were 
adjusted to the same speed. However, the machinery itself was different as the UT 18 has more 
power, which can be attributed to its superior motor.  
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As expected, the particle size was influenced by the different dispersing instruments. The 
microparticle samples that were prepared with ultrasound had the smallest particle size; the 
samples with UT 18 were smaller compared to the ones prepared with UT 8. 
 
Table 23: Influence of emulsification method during emulsification of primary emulsion on 
particle size and encapsulations efficiency (mean ± SD, n = 3) 
Sample Emulsification 
method for 
primary emulsion 
D10 [µm] D50 [µm] D90 [µm] Encapsulation 
efficiency [%] 
M1 Ultrasonication 1.9 ± 0.8 14.2 ± 6.3 81.1 ± 59.9 83.9 ± 2.0 
M2 UT 8 13.7 ± 0.6 34.6 ± 6.1 92.0 ± 10.9 54.4 ± 2.5 
M3 UT 18 3.2 ± 0.3 21.3 ± 3.9 40.39 ± 0.7 83.3  ± 2.5 
 
 
The particle size of microparticles can be altered using a lot of different parameters, when a 
double-emulsion method is being applied. Especially the emulsifications steps are critical, if 
adjustments regarding the particle size are being desired.  Furthermore, the particle size of 
microparticles can be adjusted using different polymers, different polymer concentrations and 
different stabilizers.  
 
4.3.1.3 Release profile 
The microparticle samples were tested regarding their in-vitro release profile.  
The samples were incubated in PBS and tested over several weeks. An evaporation of the buffer 
during the release study was not observed, as the samples were kept in Eppendorf cups.  
An initial burst was observed for all preparations. The formulations with the smallest particle size 
(M1 and M3) showed a higher initial burst. After three days no additional release of BSA was 
observed for those particles. The microparticle formulation with the biggest particle size (M2) 
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also showed a high immediate release of over 40 %, the release continued to be over 60% after 
one week.  
The release of all formulations was not complete in the experiment, which may be attributed to 
the fact that due to hydrophobic interactions the BSA can also be adsorbed at the surface of the 
PLGA microparticles. It is also possible that a complete release of the active compound was 
simply not done after three weeks. Consequently, longer release studies need to be performed in 
the future. Release studies described in the literature had duration of 1 day to several months 
(Determan et al., 2004; Freiberg and Zhu, 2004; Uchida et al., 1995). Results in the literature 
were not in agreement with each other. Some studies showed the same release profile as 
presented in this work (Blanco and Alonso, 1998; Ravi et al., 2008; Uchida et al., 1995; Ye et al., 
2010), where a complete release was not observed. However, this is most likely due to the short 
duration of the study. In other studies it was reported that a complete release of the protein is 
possible (Giteau et al., 2008; Luan et al., 2006; Porjazoska et al., 2004).  
It must be stated that due to the acid environment in microparticles following degradation of the 
polymer the protein is highly stressed. This acid environment might also lead to the inactivation 
of the encapsulated protein. Previous studies, in which very long release profiles of several weeks 
to month were reported, must be viewed carefully, as the simple detection of the released amount 
of protein does not allow a statement on whether it remained still active. 
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Fig. 47: Dissolution test of microparticle samples M1-M3 (mean ± SD, n = 2) 
 
 
4.3.1.4 Morphology of microparticles 
The morphology of the microparticle formulations was investigated using SEM. The 
formulations with the immediate release within 3 days (M1 and M3) had a different morphology 
compared to microparticle formulation M2, which had a sustained release over two weeks.  
It must be stated that the particles of M1 and M3 formulations were also smaller than of the M2 
formulations (Table 23).  
The particles of M1 and M3 formulations had an irregular morphology. Some particles were 
spherical, but some particles had a drop like structure. In addition, the particles with the drop like 
structure were hollow. It can be stated that the bigger particles within one formulation were of a 
drop like structure and that the smaller particles were spherical in their morphology. 
The M2 formulation was very homogenous, no particles with a drop like structure were found. 
The particles were round and had a clearly visible sponge like internal morphology. This internal 
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structure is in agreement with the findings of the dissolution test, where a release of the active 
compound over two weeks was determined. Protein that was located near the polymeric shell was 
faster released than protein that was located in the inner core of the microparticle.  
 
 
Fig. 48: SEM images of w/o/w-MP: a) and b) microparticles prepared with ultrasound during first 
emulsification; c) and d) microparticles prepared with UT 18 during first emulsification; e) and 
f) microparticles prepared with UT 8 during first emulsification; samples were investigated at 
15 kV with magnifications of 400 - 1500 x 
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5 Summary and Conclusion 
 
Live, attenuated vaccines consist of virus or bacteria that are not virulent, but have the ability to 
proliferate. Therefore, a strong immune response can be generated, as the vaccine is distributed 
throughout the body, due to the proliferation properties of the microorganisms. Mutation of the 
vaccine can cause the microorganisms to reverse to virulence. Therefore, inactivated, non-live 
vaccines are more desirable on the grounds of safety issues. However, inactivated vaccines rarely 
induce a strong enough immune response to achieve adaptive immunity. That is why adjuvants 
are essential for successful vaccinations (Rosenthal and Zimmerman, 2006). 
The objective of this work was to develop protein loaded micro- and nanoparticles as parental 
carrier systems for the antigen delivery, as particulate, polymeric carrier systems have a huge 
potential to pose as adjuvants.  
Antigens can be encapsulated in microparticles, causing the active compound to be released over 
several weeks. A pulsatile release would also be possible, mimicking several injections. 
Moreover, microparticles can even be taken up by cells, if the particle size is below 10 µm 
(O’Hagan et al., 2006). 
Nanoparticles have a similar size as pathogens, making them particularly interesting for antigen 
delivery. Besides, nanoscale drug delivery systems can enhance the transport of the active 
compound across absorption barriers, leading to high amounts of antigen within dendritic cells 
and macrophages (Singh et al., 2007). 
In the presented work, microparticles were prepared with a double-emulsion solvent extraction 
method. The influence of different parameters on the microparticle properties was investigated.  
Interestingly, our findings showed that not only the first emulsification process to obtain the 
primary emulsion is decisive on the resulting particle size, but also the second emulsification 
process to obtain the double emulsion.  
Furthermore, it was discovered that microparticles that contained Span 60 as a surfactant in the 
oil phase during the preparation, had a significantly lower encapsulation rate than particles 
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without Span 60. Instead of stabilizing the interfaces Span 60 increased the leakage of the protein 
from the inner phase to the outer water phase, yielding in low encapsulation rates.  
In this work, a physicochemical characterization of nanoparticulate drug carriers was performed 
to better understand their properties. Protein loaded nanoparticles were prepared using a double-
emulsion-method. This technique has been widely described as a simple method to encapsulate a 
hydrophilic drug inside polymeric nanoparticles (Blanco and Alonso, 1997; Lamprecht et al., 
2000b). Moreover, this preparation method is manageable in a laboratory scale, as expensive and 
big instruments are unnecessary. Many in-vivo studies for various medical applications have 
been performed with nanoparticles prepared by this method (Jiao et al., 2002; Kasturi et al., 
2011).  
The biocompatible and biodegradable PLGA, which is an excipient that has already been used in 
pharmaceutical products, was used as a polymer and BSA was used as a model protein. First, 
nanoparticles were prepared using different amounts of stabilizer, in this case PVA, in the outer 
water phase. It was observed that the mean diameter of the prepared particles decreases with 
increasing PVA concentrations. At a concentration of 0.03% PVA in the outer phase, 
microparticles were prepared. By increasing the PVA amount to 0.1%, nanoparticles were 
obtained. Higher PVA concentrations led to a decrease of the particle size of the nanoparticles. 
Interestingly, the loading rate of the nanoparticles with BSA was almost proportional to the mean 
diameter of the nanocarriers. The loading rate increased with smaller obtained nanoparticles. This 
effect is not in accordance to the theory that the active compound is encapsulated inside the 
nanoparticles. To analyze the loading behavior in detail, the preparation method was modified in 
the regard that the protein was not present in the inner water phase, but was later added to the 
outer water phase. For this modified version of the double-emulsion method, the protein was 
definitely located at the surface of the nanoparticles. Surprisingly, the loading rates for these 
nanoparticles showed a similar behavior compared to those prepared in the conventional way. 
Further testing regarding the release profile strengthens the suspicion that the protein is not 
encapsulated, but located at the surface. A fast release within one hour was observed, and the 
release profiles of the particles prepared by the conventional method were identical to those 
prepared by the modified version. A sustained release could only be determined for particles with 
a mean diameter in the micrometer range. Here, some part of the protein seems to be 
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encapsulated, as a complete release was not observed after 24 hours. To get a comprehensive 
understanding of the prepared particles, FE-SEM was used to investigate the morphology of the 
particles. In previous studies, the imaging techniques were used to determine the shape of 
nanoparticles and to confirm the particle size (Sahana et al., 2010; Zambaux et al., 1998). 
However, the internal morphology was never visualized. Therefore, ion-milling coupled FE-SEM 
was used to reveal the morphology of the nanoparticles. Furthermore, the model protein BSA was 
substituted with Gold-BSA as Gold-BSA is visible as bright spots in FE-SEM images. The 
internal morphology was clearly visible using this method and it was observed that most of the 
gold-labeled protein was located at the surface of the nanoparticles. It was revealed that only 
particles with a mean diameter above 600 nm contained an inner phase. Thereby, the previously 
postulated structure of nanoparticles prepared by the double-emulsion method needs to be 
revisited.  
It can be concluded that ion-milling coupled field-emission scanning electron microscopy is a 
novel approach to characterize nanoparticles and is suitable to visualize the interior morphology 
of nanoparticles, which has never been described before. The method should be applied to all 
nanoparticle formulations described in the literature that have an active ingredient encapsulated 
to determine the interior morphology.  
The findings in this work revealed that the double-emulsion method is not a proper preparation 
technique to produce nanoparticles that have the hydrophilic drug encapsulated inside a 
polymeric matrix. This should impact further studies regarding protein loaded nanoparticles as 
novel preparation methods are necessary to ensure that proteins can be encapsulated inside 
nanoparticles. 
Furthermore, it can be discussed, whether the double-emulsion technique qualifies at all as a 
proper preparation method for nanoparticles loaded with hydrophilic drugs. The method can be 
altered, by first producing polymeric nanoparticles and in a second step adsorbing the active 
compound onto the surface of the nanoparticles. Thus, shear stress, pressure and high 
temperatures can be avoided for the hydrophilic drug. 
Taking the previous discoveries into account, a simplified method was used to obtain protein 
loaded nanoparticles. The particles were prepared using an emulsification-evaporation method 
Summary and Conclusion 
 
127 
 
followed by an incubation process, in which the hydrophilic drug, in this case OVA or BSA, was 
adsorbed at the nanoparticle surface. The obtained PLGA-NP were prepared with different 
surfactants, yielding in nanoparticles with modified surface properties. The nonionic surfactants 
Tween 20 and PVA, the anionic surfactants SDS and sodium cholate and the cationic surfactant 
CTAB were utilized. The particles were characterized regarding their particle size, loading rate 
with OVA and BSA, as well as their release profile. A fast release within one hour was observed 
for all formulations. In most cases BSA was adsorbed at a higher rate than OVA on the 
nanoparticles, an exact mode of action on how the adsorption takes place is still unknown. The 
different formulations were tested regarding their toxicity and their cell adhesion properties in 
cell culture experiments. It was observed that the Tween 20-NP and the CTAB-NP showed a 
toxic potential at concentrations of 1 mg/ml, the other formulations were not toxic for the tested 
concentrations. The cell uptake of the CTAB-NP was significantly lower compared to the other 
formulations. This might be due to the fact that the other formulations were loaded with OVA, a 
loading of the CTAB-NP with OVA was not obtained as the loading rate was 0%. 
The five different nanoparticle formulations were also tested for their potential to adsorb 
Clostridium perfringes α-toxoids. Two different α-toxoids were tested. One was formalin 
inactivated α-toxoid from Clostridium perfringens and the other was expressed in genetically 
modified E.coli. Using SDS-PAGE it could be observed that both proteins were not pure, leading 
to aggregation with the cationic CTAB-NP. The anionic SDS-NP and sodium-cholate-NP were 
incompatible with the α-toxoid from Clostridium perfringens. PVA-NP and Tween 20-NP 
showed a satisfying behavior in regard to the compatibility with the proteins. Furthermore, it was 
discovered that most of the α-toxoid was adsorbed at the surface of the nonionic nanoparticles.  
The exact mechanism in which the protein adsorbs to nanoparticles is the target of many studies, 
but it has not been fully explained (Fleischer and Payne, 2012; Lynch et al., 2007). It is believed 
that the proteins arrange themselves as a “protein corona” around the nanoparticles (Lundqvist et 
al., 2011). Hydrophobic interactions seem to be the deciding force during the adsorption of 
proteins on nanoparticles (Rahman et al., 2013).  
In immunization studies with BALB/c mice the immune response following application of the 
different OVA loaded nanoparticle formulations was determined. CTAB-NP showed a 
significantly higher antibody response compared to the other formulations. This was very 
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surprising as OVA was not located at the surface of the CTAB-NP, but was just dissolved in the 
nanoparticle suspension. An increased transport into the cells with the CTAB-NP was therefore 
not likely. The second highest antibody response was elicited by Tween 20-NP, which suggests 
that the toxicity of these two formulations might be the reason for the high antibody response. 
When investigating the influence of different concentrations of the nanoparticle formulations, it 
was revealed that at the highest CTAB-NP concentration a severe inflammation at the injection 
site was visible. This suggests that a pronounced inflammation occurred, leading to an 
accumulation of cells of the immune system like dendritic cells and macrophages, which are 
crucial for adaptive immunity.  
Another adjuvant formulation that was developed were LPS-NP. LPS are TLR-4 agonists and 
therefore an interesting substance as they activate and facilitate the maturation of dendritic cells 
(Foged et al., 2002; Hamdy et al., 2011). An emulsification-evaporation method was used for the 
preparation of LPS-NP. It was determined that almost 70% of the LPS was bound on the 
nanoparticles. Using an in-vivo study the adjuvant potential of LPS-NP was investigated. It can 
be concluded that LPS-NP, when combined with CpG, was significantly beneficial regarding its 
antibody response compared to LPS and CpG in solution. These findings might be interesting for 
the development of novel adjuvants, as new TLR-ligands can be used in combination with 
nanoparticles to improve their adjuvant properties. 
The preparation of the protein loaded o/w-NP had several advantages compared to the double-
emulsion method as the protein is not exposed to shear stress and temperature, when adsorbing 
them onto the nanoparticle surface after the preparation step. It can be concluded, that simple 
adsorption of the protein onto the nanoparticle surface after preparation of the nanoparticles by an 
emulsification-evaporation method is a suitable technique to obtain protein loaded nanoparticles. 
Here, it has the advantage, compared to the double-emulsion method, that the “blank” 
nanoparticles can be freeze dried or stored at 4°C and that the incubation with the protein and 
following adsorption of the protein onto the nanoparticle surface can be carried out just before 
administration of the nanocarriers. This is a major advantage, as protein stability only has to be 
ensured for several hours as opposed to several weeks, when the protein is already part of the 
final formulation.  
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Based on the results in this work we can also conclude that the surface properties of nanoparticles 
play a critical role regarding the ability to enhance an immune response. Surfactants have to be 
selected carefully as the nanoparticle-protein interactions and the toxicity of the prepared 
nanoparticles are dependent on the chosen surfactants. It can also be concluded that the protein 
loaded nanoparticles most likely do not increase the immune response by enhancing the antigen 
delivery into the cells, but that inflammation induced by the antigen loaded nanoparticles causes a 
significantly increased immune response compared to the soluble antigen. 
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6 List of Abbreviations 
 
°C   degree Celsius 
API   active pharmaceutical ingredient 
BCA   bicinchoninic acid 
BSA   bovine serum albumin 
CFA   Complete Freund’s Adjuvant 
CLSM   confocal laser scanning microscopy 
CTAB   cetyltrimethylammonium bromide 
Da/kDa  Dalton/ kilodalton 
DMEM  Dulbecco’s Modified Eagle Medium 
DMSO   dimethyl sulfoxide 
DTT   dithiothreitol 
e.g.   Latin: exempli gratia (for the sake of an example) 
EE   encapsulation efficiency 
ELISA   enzyme-linked immunosorbent assay 
et al   Latin: et alii (and others) 
FDA   Food and Drug Administration 
FE-SEM  field emission-scanning electron microscope 
Fig.   figure 
FITC   fluorescein isothiocyanate 
g   acceleration of gravity  
G   Gauge 
h   hour 
IFA   Incomplete Freund’s Adjuvant 
IgG   immunoglobulin G 
kV   kilovolt 
LPS   lipopolysaccharides 
min   minutes 
MTT   methylthiazolyldiphenyltetrazolium bromide 
n   number, e.g. of samples 
NP   nanoparticles 
o/w   oil-in-water 
OVA   ovalbumin 
PAGE   polyacrylamide gel electrophoresis  
PAMP   pathogen associated molecular pattern 
PCS   photon correlation spectroscopy  
PDI   polydispersity index 
PLGA   polylactid-co-glycolid 
PVA   polyvinyl alcohol 
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rcf   relative centrifugal force 
rpm   revolutions per minute 
s   seconds 
s.c.   subcutaneous 
SD   standard deviation 
SDS   sodium dodecyl sulfate 
SEM   scanning electron microscope 
STIKO  german: Ständige Impfkommission des Robert Koch-Instituts 
TLR   Toll-like receptor 
w/o   water-in-oil 
w/o/w   water-in-oil-in-water 
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7 Appendix 
 
7.1 Substances 
Table 24: List of substances used in this work 
Substance Manufacturer 
Bovine Serum Albumin Boehringer Ingelheim 
CpG Invivogen 
CTAB Roth 
Disodium phosphate Sigma Aldrich 
DTT Roth 
Ethyl acetate ZVE 
FBS Sigma Aldrich 
Freund’s Adjuvant, complete Sigma Aldrich 
Freund’s Adjuvant, incomplete Sigma Aldrich 
LPS Sigma Aldrich 
Methylene chloride ZVE 
MTT Sigma Aldrich 
Nile red Sigma Aldrich 
Ovalbumin Sigma Aldrich 
Penicillin-Streptomycin Sigma Aldrich 
PLGA Evonik 
Potassium chloride Sigma Aldrich 
Potassium dihydrogen phosphate Sigma Aldrich 
PVA Kuraray 
SDS Sigma Aldrich 
Sodium chloride Sigma Aldrich 
Sodium cholate Sigma Aldrich 
Tween 20 Roth 
Tween 80 Roth 
α-toxoid Boehringer Ingelheim 
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7.2 Supplementary Tables and Figures 
 
 
Fig. 49: Chemical structure of polyvinyl alcohol 
 
 
 
 
 
Fig. 50: Chemical structure of Polysorbate 20 
 
 
 
 
 
Fig. 51: Chemical structure of SDS 
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Fig. 52: Chemical structure of sodium cholate 
 
 
 
 
 
Fig. 53: Chemical structure of CTAB 
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Fig. 54: FE-SEM images of polyaminomethylmethacrylate-NP prepared by a double-emulsion 
method at 0.7 – 0.8 kV with magnifications of 13000 – 50000 x after ion milling with an argon 
beam 
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Fig. 55: Loading rate of O/W-Nanoparticles (10 mg/ml) with 0.5 mg/ml Ovalbumin (mean 
± SD, n=3) 
 
Fig. 56: Loading rate of O/W-Nanoparticles (10 mg/ml) with 1 mg/ml Ovalbumin (mean ± 
SD, n=3) 
Appendix 
 
137 
 
 
Fig. 57: Loading rate of O/W-Nanoparticles (10 mg/ml) with 2 mg/ml Ovalbumin (mean ± 
SD, n=3) 
 
Fig. 58: Loading rate of O/W-Nanoparticles (10 mg/ml) with 0.5 mg/ml BSA (mean ± SD, 
n=3) 
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Fig. 59: Loading rate of O/W-Nanoparticles (10 mg/ml) with 1 mg/ml BSA (mean ± SD, 
n=3) 
 
Fig. 60: Loading rate of O/W-Nanoparticles (10 mg/ml) with 2 mg/ml BSA (mean ± SD, 
n=3) 
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Fig. 61: SDS-PAGE gels after staining with Coomassie Brilliant Blue, supernatants of o/w-NP 
formulations after incubation with toxoids, redispersed o/w-NP with SDS and DTT, and standard 
of α-toxoid (Clostridium perfringes): 1) Marker 2) PVA-NP supernatant 3) PVA-NP supernatant 
4) PVA-NP redispersed (4x) 5) PVA-NP redispersed (1x) 6) α-toxoid (Clostridium perfringes) 
0.0215 mg/ml 7) α-toxoid (Clostridium perfringes) 0.0161 mg/ml 8) α-toxoid (Clostridium 
perfringes) 0.0108 mg/ml 9) α-toxoid (Clostridium perfringes) 0.0054 mg/ml  
 
 
Table 25: Surface tension of surfactant solutions (mean ± SD; n = 3) 
Surfactant 
concentration 
Surface tension [mN/m] 
[g/100 ml] PVA-NP Tween 20-NP SDS-NP Sodium 
cholate-NP 
CTAB-NP 
1 44.2 ± 0.4 23.4 ± 0.2    
0.3 44.6 ± 0.4 36.3 ± 0.4    
0.1 48.9 ± 0.1 38.1 ± 0.9 61.6 ± 4.4   
0.05   68.4 ± 0.2 56.3 ± 0.2 34.0 ± 2.6 
0.035    59.5 ± 0.1 35.0 ± 0.1 
0.01   69.7 ± 0.1 61.0 ± 0.4 35.6 ± 0.1 
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Fig. 62: Uptake of o/w-NP in RAW 264.7 cells after staining with Nile red at different incubation 
periods (mean ± SD; n = 3) 
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